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ABSTRACT  
 
PROBIOTIC USE IN TRAUMA PATIENTS: A PATHWAY TO DETERMING THE 
STANDARD OF CARE TO IMPROVE OUTCOMES 
 
 
 
By 
Heather A. Vitko 
December 2018 
 
Dissertation supervised by L. Kathleen Sekula 
The gut microbiome consists of normally non-pathogenic bacteria, viruses, and 
fungi.  These friendly microbes serve to maintain GI barrier function and integrity, play a 
role in host nutrient and drug metabolism, immunomodulation, and prevent pathogenic 
bacteria from colonizing or causing disease.  The importance of a healthy microbiome for 
the overall health of the host is just recently being appreciated within the medical and 
science communities.  Disruption of the microbiome places one at greater risk for illness 
and infection. Patients who suffer a traumatic injury are among those at highest risk for 
complications associated with microbial imbalance, or dysbiosis. In addition to the 
mechanisms of traumatic injury that can impair one’s immune function, these patients are 
subjected to a variety of treatments and therapies that account for a tendency toward 
dysbiosis which can lead to healthcare-acquired infections. These include treatment with 
 v 
 
antibiotics, proton pump inhibitors, and opioids as well as therapies that require invasive 
procedures and monitoring. One suggested means to restore immune function and for the 
prevention of HAIs is to supplement patients with probiotics to restore or replenish host 
microbiota. However, despite promising findings regarding the efficacy of probiotics for 
prevention and amelioration of certain HAIs, supplementation with probiotics is not 
without risks.  
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Chapter 1 
INTRODUCTION 
Healthcare-associated infections (HAI) are a costly complication of 
hospitalization.  These infections place a significant burden on the individual and 
healthcare system in terms of morbidity, mortality, and excess costs.  Considered a 
marker of quality care, HAIs are one of the most common causes of preventable harm in 
healthcare.  According to a study by the Centers for Disease Control (CDC), more than 
one million HAIs occur each year in the United States healthcare system.  Many common 
HAIs can be prevented through certain measures, and hospitals and clinicians are 
implementing prevention strategies with some success.  However, new and novel 
approaches to the prevention of HAIs must be explored.  
Hospitalized trauma patients are at even greater risk for the development of a 
HAIs due to the nature of their injury.  Trauma sets off a massive inflammatory response 
that can weaken the patient’s immune system and can destroy gastrointestinal commensal 
bacteria, making them more susceptible to infection.  Traditionally, infections or 
suspected infections are treated with antibiotics, a practice that has contributed to the 
development of multi-drug resistant organisms.  In addition to killing pathogenic 
bacteria, they also disrupt the gastrointestinal (GI) microbiome, our “normal flora”, as 
well.  This added destruction of our gastrointestinal host defenses can contribute to the 
development of infections. 
Commercially available probiotic supplements are living organisms which contain 
a variety of bacterial and fungal species normally found in a healthy gut.  Consumption of 
these probiotic supplements can replenish depleted or destroyed GI host flora, thus 
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providing a barrier or restoring the normal immune defense to the host.  Although there is 
sufficient evidence that probiotics are effective for a variety of health ailments, it is a 
largely understudied topic with respect to consistency in strains and methods and is 
generally a new area of research in the trauma population. 
Since sepsis is a leading cause of late mortality in trauma patients, the ultimate 
goal is to prevent infections in this high-risk population.  Treatment with antibiotics once 
an infection has developed is associated with many dangers including increased cost, 
treatment failure, Clostridium infections, and the development and contribution of multi-
drug resistant organisms.  This dissertation research aimed to address the research gap by 
specifically looking at the impact the administration of probiotic supplements to 
hospitalized trauma patients has on a variety of outcomes, primarily the development of 
HAIs. 
This document is divided into the following sections: 
1.  Chapter 2 includes a published manuscript that provides an overview and 
summary of the current literature and evidence that relates to outcome measures 
associated with probiotic administration to hospitalized trauma patients. 
2.  Chapter 3 contains:  the dissertation proposal that describes the research 
project’s specific aims, research questions, background and significance, the 
theoretical framework, significance to nursing, research design and methods, 
plans for data analysis and interpretation, study limitations and challenges, and 
strategies to address threats to study validity. 
3.  Chapter 4 includes 3 manuscripts.  First, a manuscript submitted to the 
American Journal of Nursing which is under revision is included.  Next, an article 
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that has been accepted for publication in the Journal of Emergency and Critical 
Care Medicine is included.  This will publish early 2019.  Lastly, a manuscript 
written for the American Journal of Critical Care that describes the dissertation 
research study, statistical analyses, and results with discussion is included.  This 
will be submitted upon completion of the doctoral defense.     
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Chapter 2 
 During the process of my literature review and search for a guiding theoretical 
framework, I realized the ethics of using probiotic supplements for trauma patients could 
be questioned.  Despite the lack of clear clinical practice guidelines back by a robust 
body of literature, research that has been conducted in this area is very promising.  
However, case reports of adverse events still warrant caution be taken.  For that reason, I 
decided to write a manuscript that discusses not only the research that has been done with 
probiotic supplementation for trauma patients, but potential ethical dilemmas their use 
may cause.  This manuscript was accepted for publication by the American Journal of 
Trauma Nursing and appeared in the January, 2017 issue.  Copyright permission has been 
received from the Journal of Trauma Nursing.  The article follows. 
 
Vitko, H. A., Sekula, L. K., & Schreiber, M. A. (2017). Probiotics for trauma patients: 
should we be taking a precautionary approach?. Journal of Trauma Nursing, 24(1), 46-
52. 
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Abstract   
The use of probiotics in the hospital setting is largely understudied and highly 
controversial. Probiotics are living organisms that, when taken internally, can produce an 
immunomodulating effect and improve the gastrointestinal (GI) mucosal barrier. 
Although used for centuries by healthy individuals for GI health, their use in the hospital 
setting is now gaining wide attention for the prevention of infectious complications such 
as antibiotic-associated diarrhea, Clostridium difficile infections, multiple-organ 
dysfunction syndrome, and ventilator-associated pneumonia. However, current 
understanding of the efficacy of probiotics in the acute care setting is confounded by the 
inconsistencies in the literature with regard to the strain of probiotic being studied, 
optimal dosage, and timing and duration of dosing, which make the formulation of 
clinical practice guidelines difficult. Although the safety of probiotics has been confirmed 
when used for the prevention and treatment of certain diseases, practitioners remain 
hesitant to administer them to their patients, citing the lack of high-quality studies clearly 
demonstrating efficacy and safety. Infection is a cause of late death in trauma patients, 
but only recently has research been conducted on the use of probiotics specifically for the 
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prevention of hospital-acquired infections in trauma patients. In the face of such limited 
but promising research, is it reasonable to use probiotics for the prevention of infection in 
hospitalized trauma patients and improve outcomes? Use of the “precautionary principle” 
may be useful in this instance. 
Keywords: Precautionary principle, Probiotics, Trauma patients 
The purpose of this research review was to examine the potential benefits of 
probiotic supplementation for hospitalized trauma patients versus the theoretical harm 
that can be caused by their use. The broad definition, mechanism of action, potential 
benefits, and regulation of probiotics are discussed first. Safety such as theoretical 
adverse effects, case reports of infection linked to probiotic use, and possible high-risk 
populations are then discussed. Finally, ethical considerations with using probiotic 
supplements with hospitalized trauma patients are presented.  
History of Probiotics Use  
 Probiotics have been used for centuries, mostly consumed in the form of 
fermented foods, by healthy people for the prevention and treatment of a variety of 
ailments. Probiotics are living organisms, the “good bacteria” that normally resides in 
our gastrointestinal system (GI) (“microbiota”) that help maintain gut barrier function 
and serve as part of our innate and adaptive immune systems. The ingestion of probiotics 
is thought to restore and replenish host microbiota that may have been depleted from 
insults such as injury, certain medications, and diet. When there is a depletion of our 
microbiota, pathogenic bacteria can grow and flourish and cause disease. Probiotic 
organisms are capable of modifying the intestinal microbiota, thereby influencing 
physiological and pathological processes of those who ingest them. It was not until the 
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late 1900s that researchers suggested that “bad” bacteria could be replaced with “good” 
bacteria in the gut and hence the concept of probiotics was formed (Food and 
Agricultural Organization of the United Nations [FAO]/World Health Organization 
[WHO], 2001; Schrezenmeir & de Vrese, 2001). Although the WHO has defined 
probiotics as living substances that, when ingested in adequate amounts, can provide 
certain health benefits to the host (FAO/WHO, 2001), there exists no legal definition of 
just what constitutes a probiotic. The Food and Drug Administration (FDA) classifies 
them as “live biotherapeutics” (Vaillancourt, 2006), and they are now commercially 
available to the general public in a variety of forms.  
“Probiotics” is a very general term used to describe many different species and 
strains of healthy microbes. Naturally found in fermented foods such as yogurts, the 
probiotic species Lactobacillus and Bifidobacterium are the most commonly found 
organisms. These, along with other species such as the fungus Saccharomyces, are being 
commercially marketed for consumer use for the prevention of certain illnesses. Within 
each microbial species, a number of strains also exist. It is thought that certain species 
and strains have different host benefits, so the benefits of probiotics may be species-, 
strain-, dose-, and possibly time-specific. Although benefit may be demonstrated with 
one strain for a particular reason, it does not mean that this same strain can be used for a 
different ailment. In addition, the beneficial effects of any probiotic may only be realized 
if it is consumed at regular intervals, in sufficient quantities to deliver live bacteria to the 
gut, and over a period of time to repopulate the gut (Ross, Desmond, Fitzgerald, & 
Stanton, 2005).  
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Regulation of Probiotics  
 Although many health care clinicians believe that probiotics have certain benefits 
for their patients, many are reluctant to use them for patients or in clinical trials 
(Williams, Ha, & Ciorba, 2010). This is not surprising, considering that the current 
regulatory framework under which probiotic supplements fall may discourage researchers 
from conducting trials on their therapeutic benefits. The FDA does not provide strict 
oversight over the use of probiotics, as they usually are considered a supplement. The 
only FDA oversight for any supplement is that safe manufacturing practices are to be 
maintained to ensure products are free from contaminants. Manufacturers do not have to 
prove therapeutic dosage, nor efficacy claims (Vaillancourt, 2006). Probiotics are 
considered by the FDA to be “generally regarded as safe,” although there are case reports 
in the literature where the development of infection in certain high-risk people has been 
linked to the use and misuse of probiotic supplements (Hempel et al., 2011;  Salminen et 
al., 2004;  Thygesen, Glerup, & Tarp, 2012) .  
 However, in the strictest sense, besides supplements, probiotics may fall under 
other FDA categories including foods, biologics, or drugs—depending on their intended 
use (Vaillancourt, 2006). There is some question in the health care community as to 
whether probiotic supplements should actually be regulated by another agency, such as 
the Center for Food Safety and Applied Nutrition (Hoffmann et al., 2013) , or if 
Investigational New Drug (IND) applications should be submitted to the FDA prior to 
clinical research with them. In the strictest sense, probiotics are dietary supplements, 
naturally occurring in food, and were marketed as such prior to 1994 when IND 
requirements were first instituted. Therefore, some argue that FDA-assigned IND 
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numbers should not be required (Hoffmann et al., 2013), even though research with 
probiotics may technically classify them as a drug. However, the FDA defines a drug as 
“a substance intended for use in the diagnosis, cure, mitigation, treatment, or prevention 
of disease or a substance (other than food) intended to affect the structure or any function 
of the body” (“Drugs@ FDA Glossary of Terms,” 2012) . In this sense, probiotics are a 
“food,” although they are commercially prepared, and would not be classified as a drug, 
although they are being used for prevention and treatment of illness.  
 Although most research with probiotics demonstrates effectiveness and safety, 
there is not an absolute consensus of such in the literature and results may differ even 
when the same probiotic species and strain have been used. One possible explanation for 
the varying results of clinical studies regarding the efficacy of probiotic supplements may 
again lie with the lack of regulatory oversight. Because probiotics are living organisms 
and not chemical substances, they are dynamic and are vulnerable to problems with 
viability and degradation. Not only these largely are dependent upon manufacturing, 
handling, and storage practices but these can also be influenced by the human host (H ill 
et al., 2014; Ross et al., 2005; Sarkar, 2016). Without strict regulatory oversight, such as 
is provided with FDA-approved drugs, many products may not possess the properties that 
were intended when manufactured. Currently, manufacturers are to declare the genre and 
species of probiotics in their product but not the viable levels of the populations (Sarkar, 
2016).  
Current Research with Probiotics  
 Much of the research on probiotic use has been conducted on otherwise healthy 
individuals. Although much of this research is not scientifically robust, the use of these 
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“good bacteria” has been linked to improvement in many conditions ranging from GI 
irregularity and certain environmental allergies to prevention of secondary Candida 
infections. With the growing interest in probiotic supplementation for the benefit of 
strengthening and altering host immunity, recent research has been conducted in the 
inpatient setting on acutely ill patients with the goal of preventing infections.  
 The majority of hospital research that has been conducted with probiotics is with 
their use for the prevention of antibiotic-associated diarrhea and Clostridium difficile (C. 
diff) infections. Much of this research has shown benefit for children and is now gaining 
momentum in the adult population. The most widely used species were Lactobacillus and 
Saccharomyces boulardii (a yeast), although many other species and strains were also 
used. A 2013 Cochrane Review that examined 23 randomized controlled trials (RCTs) 
conducted in children and adults found that probiotics are both safe and effective for the 
prevention of C. diff diarrhea (Goldenberg et al., 2013). More recent meta-analyses 
conducted in 2015 (McFarland, 2015b) and 2016 (Lau & Chamberlain, 2016) again 
concluded that the administration of probiotics was effective for preventing primary C. 
diff infections associated with antibiotic use. In 2016, Shen et al. also performed a meta-
analysis of 18 RCTs that involved 6,129 adult hospitalized participants. There is a clear 
lack of homogeneity between these studies; 9 different species and strains were used in 
the various studies. Despite that, however, the authors concluded that not only were the 
various probiotics effective for the prevention of C. diff infections but also there were no 
reports of probiotic-related sepsis in any of the studies (Shen et al., 2016).  
 Another area of inpatient probiotics research is for the prevention of ventilator-
associated pneumonia (VAP). Most commonly, strains of the Lactobacillus species have 
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been studied in mechanically ventilated patients who are at risk for the development of 
VAP. A meta-analysis published in 2010 (Siempos, Ntaidou, & Falagas, 2010) found a 
39% reduction in the VAP rate with the administration of probiotics. Two other RCTs 
conducted since that publication (Barraud et al., 2010; Morrow, Kollef, & Casale, 2010) 
had conflicting results. Although Morrow et al. (2010) found that patients who were 
treated with probiotics had a lower incidence of VAP, Barraud et al (2010) found no 
difference between the probiotics and placebo groups. Again, however, results are 
difficult to combine and generalize due to significant heterogeneity in these studies. 
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Research with trauma patients is fairly new, so there are very few published 
studies. Outcome assessment for these studies not only generally focused on overall 
hospital-acquired infections but also examined secondary outcomes such as VAP, length 
of stay (both intensive care unit [ICU] and hospital), and mortality rates. Results of these 
RCTs are summarized in Table 1. Overall, the administration of probiotics to trauma 
Table 1  *Synbiotic Forte (Medipharm, Kagerod, Sweden, and Des Moines, IA) 
Contains Lactobacilli  + Bioactive Fibers:  Pediococcus pentosaceus ,  
Leuconostoc mesenteroides ,  Lactobacillus paracasei , and  Lactobacillus 
plantarum  
Author (Year)  Patient 
Population  
Species  Outcomes 
Measures  
Findings  
Falcao de Arruda & 
de 
AguilarNascimento 
(2004)  
TBI patients 
with enteral 
feedings  
 Lactobacillus 
johnsonii  
Incidence of 
infection, ICU 
LOS, days of 
mechanical 
ventilation  
Decreased 
infection 
rate and 
ICU LOS  
Kotzampassi et al. 
(2006)  
Multiple 
trauma, 
mechanically 
ventilated/ 
ventilator 
support  
Synbiotic 2000 
Forte  
Infection rate, 
SIRS, sepsis, 
mortality, ICU 
LOS, days of 
mechanical  
ventilation  
Decreased 
infection 
rate, SIRS, 
sepsis, and 
mortality  
Spindler-Vessel et 
al. (2007)  
Multiple trauma 
patients  
Synbiotic 2000 
Forte*  
Changes in 
intestinal 
permeability, 
infection rate, 
mortality, ICU 
LOS, 
mechanical 
ventilation days, 
occurrence of 
multiple-organ 
failure  
Fewer 
infections, 
lower 
intestinal 
permeability  
Tan et al. (2011)  TBI patients 
with enteral 
feedings  
 Bifidobacterium 
longum  +  
Lactobacillus 
bulgaricus  +  
Streptococcus 
thermophilus  
Infection rate, use 
of antibiotics, 
ICU LOS, 28-
day mortality 
rate  
Decreased 
incidence of 
nosocomial 
infections 
and  
ICU LOS  
 Note: ICU = intensive care unit; LOS  = length of stay; SIRS  = systemic inflammatory 
response syndrome; TBI  = traumatic brain injury. 
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patients has demonstrated positive outcomes for these patients, although there also is a 
lack of homogeneity in these studies. It may be reasonable to utilize outcomes of 
research with acutely and critically ill patients and generalize these findings to trauma 
patients; however, generalizability is not easily done. Different probiotic species and 
strains were used; different strengths, timing of administration, onset of first does, and 
duration of use vary widely among the studies. In addition, in many of the studies, the 
authors did not provide clear definitions, nor diagnostic criteria for what constitutes a 
hospital-acquired infection or VAP. Research with probiotics specifically in the trauma 
patient is certainly warranted. However, risks versus potential benefits must be 
considered.  
 Potential Risks Associated with Probiotics Use  
Because probiotics have been primarily used by healthy people to improve GI 
function, their use in acutely ill patients does not come without controversy. The most 
commonly reported adverse effect associated with their consumption is mild GI effects 
such as abdominal cramps, flatulence, and nausea. However, more concerning adverse 
effects also have been sporadically reported. Because probiotics are living organisms, 
typically composed of bacteria and fungi, they theoretically could stimulate an excessive 
immune response in certain susceptible individuals or could cause an infectious process 
if they somehow establish outside of the GI system. These, along with some published 
case reports of probiotic-associated bacteremia, have led to safety concerns among some 
health care practitioners. Although the overwhelming majority of studies demonstrate 
that probiotic supplements are well tolerated and safe for use even in acutely and 
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critically ill patients, there are case reports that describe systemic infections thought to be 
linked with probiotic use.  
 There are more than 30 published case reports of Saccharomyces -positive blood 
cultures in patients receiving this probiotic species (Didari, Solki, Mozaffari, Nikfar, & 
Abdollahi, 2014; Doron & Snydman, 2015) and at least 8 cases of  Lactobacilli 
bacteremia associated with its consumption (Doron & Snydman, 2015). In some of these 
cases, the patient also had a central venous access device, prompting experts to question 
if the method of entry into the bloodstream was the hands of the health care worker who 
was handling the probiotic. Therefore, strict adherence to hand washing and gloving 
when handling probiotic supplements to prevent this contamination should be strictly 
observed.  
 In 2011, Hempel et al. conducted an exhaustive review of the published 
probiotics literature. Sponsored by the National Institutes of Health and the FDA, this 
review included 622 studies of six probiotic species (Lactobacillus, Bifidobacterium, 
Saccharomyces, Enterococcus,  Bacillus, and  Streptococcus), which concluded there is 
no evidence of increased risk to safety with the use of probiotics. However, the authors 
also stated that published studies do not consistently assess and report on safety of their 
studies, so researchers cannot assume absolute safety with the use of probiotics in 
intervention studies (Hempel et al., 2011).  
 On the basis of case reports, there is a certain population that may be considered 
“at risk” for safety issues with the administration of probiotic supplements. A systematic 
review on the safety of probiotics conducted in 2014 (Didari et al., 2014) examined 
published literature from 1984 through May 2013. It found overwhelming evidence that 
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suggests probiotics are safe, but certain high-risk populations may incur complications 
such as systemic infection and even death. These populations include 
immunocompromised patients and those who are critically ill. Populations that have been 
suggested by the FDA to be at risk also include those with structural heart 
disease/mechanical valves and patients with the potential for the translocation of the 
probiotic across the bowel wall such as the presence of an active bowel leak (Doron & 
Snydman, 2015). Positive effects, however, have also been found in these high-risk 
populations that were given probiotic supplementation, so a risk–benefit ratio must be 
considered before electing to use them in any high risk group.  
Ethical Issues/Controversy  
 In the pursuit of evidence-based practice, there is a certain element of risk that 
must be assumed when researching new ideas, technologies, and drugs. This risk, 
however, must be minimalized and every effort should be made to weigh the risk–benefit 
ratio of pursuing new treatments. “First, do not harm” is an axiom at the root of medical 
and pharmacological education and is used to serve as a reminder to clinicians that every 
medical decision carries with it an element of harm (Smith, 2005). The goal in medical 
research is to use available knowledge to formulate hypotheses that can be used to 
potentially prevent, treat, or ameliorate illness and disease. Oftentimes, as with any new 
ideas, benefits must outweigh risks in the absence of true clinical certainness. But does 
not having enough evidence to support the use of probiotics justify not using them at all? 
Especially, when the majority of published studies show benefit with minimal risk of 
harm? It has been questioned whether cost–benefit analysis is appropriate for health 
regulation and policy making, especially when the assessed value is associated with 
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improved health and outcomes (Arrow, Cropper, Eads, & Hahn, 1996). Although the 
“precautionary principle” was developed and is usually applied in the context of 
environmental protection and global policy making, it may have applicability in health 
care decision making.  
 In 1998, the Wingspread Conference was convened to discuss and reach an 
agreement on the precautionary principle and its application in public health and 
environmental decision making (“Wingspread Conference on the Precautionary 
Principle,” 1998). Participants in this conference came from a wide variety of disciplines 
and interest groups including environmental activists, scientists, and scholars from the 
United States, Europe, and Canada. Prior to this meeting, policies were aimed at 
allowing new technologies to be implemented on the basis of risk assessments, but many 
times these technologies or actions were later proven to be harmful. The precautionary 
principle aimed to put the burden of proof upon the scientists and companies that any 
activities they pursue were reasonably considered to be “harmless” and that these 
scientists are to be held accountable if any harm should occur. The principle was 
intended for the protection of the public and the environment when technologies were 
implemented or actions were taken that could negatively affect the public. Therefore, the 
basic element is that in the absence of scientific certainty, the onus of responsibility that 
chances of harm are minimized falls on the researcher. In other words, when an action 
can potentially pose a threat to human health, precautionary measures should be 
undertaken even if cause and effect relationships have not been fully established or are 
not clearly understood. Therefore, scientists would adopt a precautionary approach when 
implementing any medical treatment that lacks scientific certainty (Adler, 2002). 
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Without scientific inquiry, new evidence and new prevention and treatment strategies 
can never be realized, but proposed treatment should be based on sound hypothetical 
reasoning. Although absolute scientific certainty rarely can be found, it is clear that more 
research into the use of probiotics for trauma patients must be done. Therefore, in one 
interpretation and application of the precautionary principle, the use of probiotics being 
administered to patients in the acute care setting may fall under these auspices.  
 Clinical trials that have been conducted to date have overwhelmingly shown 
reduction in the incidence of hospital-acquired infections among certain patient groups 
that received probiotics during hospitalization (Barraud et al., 2010; Curtis & Epstein, 
2014;  Enomoto, Larson, & Martindale, 2013;  Gu, Deng, Gong, Jing, & Liu, 2013) . 
Although several studies over the past decade have mostly demonstrated both efficacy 
and safety of probiotic supplementation, there is a clear lack of homogeneity in the 
research and many studies are based on small sample sizes. Therefore, any results 
whether favorable or unfavorable must be interpreted cautiously. Although it cannot be 
said that there is an absolute absence of risk associated with the administration of 
probiotic supplements to acutely ill patients, what medical therapy exists that carries an 
absolute absence of risk associated with its use? Potential for harm must be recognized 
and every effort must be made to prevent risk. When administering probiotics to acutely 
ill trauma patients, doing so should encompass careful consideration as in all high-risk 
populations. Monitoring parameters for nurses and physicians regarding potential 
untoward effects associated with probiotic administration, when to halt the use of the 
probiotics, and when to initiate laboratory testing is warranted.  
  
26 
 
 Caution must be used when making decisions regarding the administration of 
probiotics to acutely ill patients, especially high-risk populations such as those patients 
who are critically ill, are severely immunocompromised, have acute pancreatitis, and live 
with mechanical heart valves or structural heart defects and those with major bowel 
surgery (Doron & Snydman, 2015; Hempel et al., 2011) . Therefore, although an 
absolute causal relationship has not been established between the administration of 
probiotic supplements and adverse effects, it is reasonable to be cautious and consider 
the utilization of any probiotic through a heuristic process until further evidence is 
published that would provide better guidance. Reasonable measures such as exclusionary 
criteria for high-risk populations and strict monitoring parameters and interventions must 
be undertaken to avoid a serious threat to human health.  
 Adopting the precautionary principle in its strictest form can stifle discovery. At 
its extreme, the principle calls for avoiding risk and the elimination of the use of 
substances that have not been proven to be safe, even if a causal link between the 
substance and harm has not been proven or lacks sufficient evidence (COMEST, 2005). 
If scientists focus solely on the risk associated with the administration of probiotics to 
acutely ill patients, then infection rates could continue to climb. Therefore, the risks that 
may be associated with the administration of probiotics to hospitalized patients should be 
weighed against the benefit that they may prevent deadly and costly hospital acquired 
infections. Currently, there is little evidence to support that probiotics cause harm 
(Hempel et al, 2011). Infection is a leading cause of late death after trauma; therefore, 
measures aimed at preventing infection are important to undertake. Hospitalized patients 
with traumatic injuries are at increased risk for infection, not only due to the nature of 
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their injuries that cause interruption of skin integrity and impaired host defense 
mechanisms but also from tissue hypoperfusion as a result of hemorrhage and multiple 
invasive procedures. In addition to the increased morbidity and mortality associated with 
infection, there is considerable financial burden to the health care system.  
 In a study based on the Healthcare Cost and Utilization Project Nationwide 
Inpatient Sample, Glance, Stone, Mukamel, and Dick (2011) reviewed the records of 
155,910 trauma patients who incurred a hospital-acquired infection and found that they 
experienced longer lengths of hospital stays, increased mortality rates, and increased 
costs associated with their care. According to various online sources and in-store costs, 
the daily cost of probiotic supplementation averages approximately $2.00 per patient, 
whereas the cost to treat a hospital-acquired infection is $9.8 billion each year, averaging 
$11,000–$45,000 per patient depending on the infection site (Zimlichman et al., 2013).  
Summary  
 There is growing interest in repopulating the human GI tract with “good 
bacteria” for immune system health. Prevention of infection in hospitalized trauma 
patients is imperative to improve outcomes, and there is a modest body of evidence to 
support that probiotic supplementation in this patient population is beneficial to achieve 
this goal. Because the research into probiotic use is relatively new, and there is a clear 
lack of homogeneity in published trials, one must cautiously interpret results from pooled 
estimates of risk where different types of probiotic strains, dosages, durations, etc., have 
been used to derive findings (McFarland, 2015a). Because researchers cannot clearly 
conclude that probiotic supplementation in the trauma population should be used to 
improve outcomes and carry relatively low risk for untoward adverse effects, efforts 
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should be made to aggressively monitor for and identify risk to human health that could 
have a causal relationship to probiotic administration. Recognizing the potential benefits 
of probiotic supplementation to hospitalized trauma patients while protecting those who 
could potentially be harmed by their administration is in line with the guidelines of the 
precautionary principle.    
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Introduction 
Healthcare-associated infections (HAI) are a costly consequence of 
hospitalization, with increased financial costs as well as increased morbidity and 
mortality for the patient.  Traditionally, infections or suspected infections are treated with 
antibiotics, a practice that has contributed to the development of multiple-drug resistant 
organisms.  Antibiotics kill not only pathogenic bacteria but our host microbiome, or 
normal flora, as well.  This destruction of our gastrointestinal (GI) host defenses can 
contribute to the development of infections. 
Even in the absence of antibiotic use, certain patient populations are at risk for the 
development of HAIs due to the nature of their injury.  Trauma patients are one such 
population.  Traumatic injury causes a massive inflammatory response that destroys GI 
commensal bacteria and weakens host defense mechanisms.   
Probiotics are living organisms which are commercially available that contain a 
variety of bacterial and fungal species normally found in a healthy gut.  The on-going 
theory is that ingestion of probiotics assists in immune function by restoring depleted 
normal flora.  Although there is sufficient evidence that probiotics are effective for a 
variety of health ailments, it is a largely understudied topic with any homogeneity and is 
a very new area for research in the trauma population. 
Since infection is a leading cause of late mortality in trauma patients, the ultimate 
goal is to prevent infections in this high-risk population.  Treatment with antibiotics once 
an infection is present is associated with many dangers including increased cost, 
treatment failure, Clostridium difficile (C. diff) infections, and the development and 
contribution of multiple-drug resistant organisms.  For these reasons, a “Probiotics 
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Protocol” was designed and implemented at a 500 bed Level 1 trauma center in south 
western Pennsylvania whereas all trauma patients meeting inclusion criteria would be 
given two different probiotic supplements (See Appendix A).  All the attending trauma 
surgeons agreed with ordering probiotics for their patients that met inclusion criteria.  
The aim was to decrease overall infection rates in the trauma patients in this hospital.  
The protocol must be ordered by the physician, physician resident, or trauma Nurse 
Practitioner as it was not included in the trauma electronic order set.  At the time of the 
initiation of the protocol, the hospital was in the midst of changing electronic medical 
record keeping software, and no new order sets were being incorporated into the old 
software/system.  As a result, clinicians had to complete a paper order sheet which was 
then faxed to pharmacy and transcribed into the computer.   
At this hospital, residents rotate through services and typically are on the trauma 
service for only one month at a time.  As residents rotated through the trauma service, the 
group exiting was responsible for communicating the use of the protocol and the 
necessary steps for implementation to the incoming group of residents.  Additionally, the 
trauma attending physicians also were to instruct the incoming residents on this protocol.  
For various reasons, including those discussed previously, the protocol had not always 
been followed.              
In order for the protocol to be implemented into the trauma admission order set, it 
needed to go through a series of committees for approval.  Initially, the implementation 
of the protocol was met with considerable resistance from some members of the 
healthcare team, namely one clinical pharmacist and an infection control physician.  
Therefore, a meeting was held between those clinicians and members of the trauma team 
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(which was comprised of 3 trauma attending physicians, a clinical pharmacist, and this 
researcher) whereas literature was produced that demonstrated efficacy with minimal risk 
to harm to the patient population.  After this input was provided into the probiotic 
administration protocol, the protocol was taken to the critical care/trauma committee and 
was approved for implementation.  However, the protocol remained as a written protocol 
whereas the trauma admission orders were electronic. 
Another hurdle with implementing the protocol with trauma patients involved 
computerized physician ordering software for the probiotic supplements.   It was 
discovered after the initial implementation of the protocol date that the probiotics specific 
for the protocol (Lactobacillus GG, Culturelle® and Saccharomyces boulardii, 
Florastor®) were not easily found in the pharmacy database.  This necessitated that 
prescribers search for the particular probiotic formulations in the database which often 
resulted in incorrect variations and frequency of probiotics being ordered.   
It was not until January 2018 that the protocol was incorporated into the 
electronic trauma admission orders.  Data collection for this research concluded in 
December 2017.    After preliminary statistical analyses were run, it was apparent that 
due to the low numbers of patients who actually received probiotics, statistical 
significance could not be affirmed.  Therefore, an extension of data collection through 
June 2018 was requested and granted by the IRB at both Duquesne University and 
Memorial Medical Center.  Additionally, data extracted from the former medical record 
system/software (prior to 2017) was not suitable for statistical analyses due to a multitude 
of factors surrounding incomplete data collection. 
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Specific Aims  
The purpose of this research study was to identify the impact of probiotics on 
certain health-related outcomes for hospitalized trauma patients.  Specifically, the 
outcomes of healthcare-associated infections such as the incidence of pneumonia and 
ventilator-associated pneumonia (as applicable), C. diff infections, urinary tract 
infections, and bloodstream infections/bacteremia, as well as hospital length of stay, 
mortality, and mechanical ventilation days (as applicable) was measured.  Not all trauma 
patients require mechanical ventilation, however for those who do, preventing ventilator-
associated pneumonia is paramount.  
 Outcome measures:   
Healthcare-associated infections (HAIs) 
 Pneumonia (PNA) 
 Ventilator-associated pneumonia (VAP) 
 Clostridium difficile (C. diff) infections 
 Urinary tract infections (UTIs) 
 Bloodstream infections/Bacteremia (BSI) 
Probiotic usage 
Hospital length of stay (LOS) 
Days of mechanical ventilation (MV days) 
Mortality 
Antibiotic requirements 
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Research Question: Does the administration of probiotic strains Lactobacillus rhamnosus 
GG (LGG, Culturelle®) and Saccharomyces boulardii (S. boulardii, Florastor®) to 
hospitalized trauma patients improve the incidence of infections and their outcomes? 
The specific aims of this research are as follows: 
1.  To determine whether administering the dual probiotic strains LGG and S. 
boulardii to trauma patients would reduce the incidence of hospital-acquired 
infections. Specific infections include:  pneumonia, ventilator-associated 
pneumonia (in mechanically ventilated patients), urinary tract infections, blood 
stream infections/bacteremia, and Clostridium difficile infections. 
2. To measure compliance with ordering probiotics (probiotics usage) 
3. To determine whether administering the dual probiotic strains LGG and S. 
boulardii to trauma patients will affect the hospital length of stay, hospital 
mortality, and MV days (as applicable). 
4. To determine whether antibiotic usage is different between patients receiving 
probiotics or not. 
Goals of this study include: 
1.  Decrease the incidence of healthcare-associated infections. (Assessed by tracking 
data retrospectively) 
2. Decrease trauma patients’ length of stay. 
3. Gain a better understanding of the role of probiotics in the acute care setting to 
improve other outcomes for trauma patients.  
 
Probiotics have been used in other acute care populations with mostly favorable 
results, therefore the research hypothesis is that administering probiotics to trauma 
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patients will improve health-related outcomes.  The long-term goals of this research are 
to determine if the use of probiotics for trauma patients will reduce the incidence of 
infectious complications.  Results, coupled with what is already known in the field of 
probiotic use in the acute care setting, may be used to develop the best evidence-based 
protocol for trauma patients with regard to the aforementioned outcomes. 
Background and Significance  
Probiotics are living microorganisms that, when taken internally, can produce an 
immunomodulating effect and improve gastrointestinal mucosal barrier function through 
replenishing lost flora.  Their use in the hospital setting is gaining worldwide attention for 
preventing infectious complications and improving outcomes in patients.  Infection is a 
leading cause of late death (death which occurs more than a week after the initial 
traumatic injury) in trauma patients (Pfeifer, Tarkin, Rocos, & Pape, 2009).  In many 
cases, traumatic injury disrupts not only the mechanical barriers that prevent infection, 
but the biological defense mechanisms as well (Hietbrink, Koenderman, Rijkers, & 
Leenen, 2006; Rijkers, 2011), causing immunological dysfunction and hyper-
inflammatory responses that can alter immune function.  This places trauma patients at an 
even greater risk for the development of a healthcare-associated infection.  Over the past 
10 to 15 years, several published studies have focused on the administration of probiotics 
to hospitalized patients. However, these studies clearly lack homogeneity with respect to 
species and strain selection, timing of initiation and duration of probiotic administration, 
and probiotic dosages.  Further, only recently has research regarding the use of probiotics 
specifically for trauma patients been conducted.  This proposed research will contribute 
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to the knowledge that currently exists and focus on the question, “can probiotics prevent 
infection and improve outcomes in trauma patients?” 
It is becoming increasingly clear that probiotics have a beneficial effect on 
immunity and their clinical use in the hospital setting is gaining worldwide attention.  
Probiotics are living organisms that, when ingested in certain amounts, can provide 
certain benefits to humans (FAO/WHO, 2001) such as modulation of immune function 
(Doron & Gorbach, 2006; Isolauri, Sütas, Kankaanpää, Arvilommi, & Salminen, 2001; 
Macintyre & Childscymet, 2005; Tan, Zhu, Du, Zhang, & Yin, 2011).  This change in 
immune function produces an immuno-protective effect that can aid in the prevention of 
infection.  Clinical trials that have been conducted to date have overwhelmingly shown 
reductions in the incidence of hospital-acquired infections among certain patient groups 
that received probiotics during hospitalization (Barraud, Bollaert, & Gibot, 2013; Curtis 
& Epstein, 2014; Enomoto, Larson, & Martindale, 2013; W. J. Gu, T. Deng, Y. Z. Gong, 
R. Jing, & J. C. Liu, 2013), yet some health care providers remain reluctant to use them 
for their acutely ill patients (Williams, Ha, & Ciorba, 2010), citing the scientific 
uncertainty that surrounds the use of probiotics due to the lack of sufficient high-quality 
studies.  Cause and effect relationships with probiotics use in the acute care setting have 
not been fully established and are not completely understood.  However, as with any new 
ideas, benefits must outweigh risks in the absence of true clinical certainness; especially 
in the case where not having evidence does not justify inaction.  The use of probiotics in 
the hospital setting remains a largely under-studied and highly controversial topic. 
Probiotics have been utilized for centuries and have been shown to have a good 
safety profile, demonstrating effectiveness for a wide variety of ailments.  A  study 
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commissioned by the Agency for Health Care Research and Quality (AHRQ) confirms 
the safety of probiotics and efficacy for prevention and treatment of certain diseases, 
although the researchers acknowledge that published studies have limited safety reporting 
(S. Hempel, Newberry, S., Ruelaz, A., Wang, Z., Miles, J.N.V., Suttorp, M.J., Johnsen, 
B., Shanaman, R., Slusser, W., Fu, N., Smith, A., Roth, E., Polak, J., Motala, A., Perry, 
T., and Shekelle, P.G., 2011).  Probiotics are not considered to be a pharmaceutical 
formula, but rather “dietary supplements” or “medical food”, depending upon their use.  
Because they not considered to be medications, they are not stringently monitored and 
controlled by the Federal Drug Administration (FDA).  The only FDA oversight for any 
dietary supplement or medical food calls for safe manufacturing practices and quality 
control measures to assure these products are made using good manufacturing practices 
with regards to sanitation, and the identity, purity, quality, strength, and composition are 
as labeled (Venugopalan, Shriner, & Wong-Beringer, 2010).  Manufacturers may make 
claims on the label such as “supports digestive health”, however they do not have to 
prove therapeutic dosage nor efficacy claims (Vaillancourt, 2006).  This is an important 
consideration when using probiotics; without strict regulatory FDA oversight, labeling 
and content may differ with considerable variation.  This included viability of the 
supposed living microbes in the container.  Shelf life and strain survival are dependent 
upon many factors.  Manufacturing, storage, and handling practices can impact stated 
dosage and strain viability as listed on the manufacturers’ packaging (Huys et al., 2006; 
Theunissen, Britz, Torriani, & Witthuhn, 2005) which may lead to inaccurate and 
inconsistent research results.  Further, packages may contain unlabeled microbes, 
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different amounts of live microbes, or may contain pathogenic micro-organisms if proper 
sanitation is not maintained during the manufacturing process. 
Another difficulty lies with the likelihood that certain diseases and illnesses may 
respond to specific strains of probiotics.  Much of the research being conducted uses a 
variety of species and strains.  The diversity of commercially available probiotic products 
is expanding, as is the variety of strains which are being studied.  Lack of homogeneity in 
species and strains in current research makes it nearly impossible to claim efficacy based 
on pooled estimates.  That is to say, not all strains are effective for every ailment.  
Further, it appears that some specific benefits of probiotic strains are also species-
dependent (S. J. Salminen, Gueimonde, & Isolauri, 2005).  There is strong evidence that 
the efficacy of probiotics is both strain-specific and disease-specific therefore any one 
probiotic may not fill all needs (L. V. McFarland, Evans, C. T., & Goldstein, E. J. , 
2018). 
Research suggests that certain probiotics offer promise for prevention of 
antibiotic-associated diarrhea, C. diff infections, multiple organ dysfunction syndrome, 
and ventilator-associated pneumonia (Alexandre et al., 2014; Bonten, 2010; Friedman, 
2012; Johnston BC, 2012; Katz, 2006; Kogan; L. V. McFarland et al., 1994).  Current 
understanding of the efficacy of probiotics in the acute care setting, however, is 
confounded by the inconsistencies in research with regard to the strain of probiotic being 
studied, optimal dosage, initiation and duration of dosing.  Further, few high-quality 
studies have been conducted; suboptimal study populations, short duration of studies, 
differences in timing of initiating probiotic administration, and questionable statistical 
analysis methods have all been questioned by the research community.  To date, two 
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readily available species of probiotics that are also consumer-popular are most commonly 
used.      
A review of the literature shows the majority of probiotics researchers focus on 
antibiotic-associated diarrhea (AAD) and C. diff prevention and treatment, with the most 
widely studied strains being S. boulardii and LGG (L. V. McFarland et al., 1994; Shan et 
al., 2013; Surawicz et al., 2000; Tung, Dolovich, & Lee, 2009).   S. boulardii has mostly 
been studied in adults, whereas the large majority of published trials with LGG were 
conducted on children and infants.  All of these studies have demonstrated a favorable 
safety profile, although there have been a few case reports of LGG bacteremia (Boyle, 
Robins-Browne, & Tang, 2006; Husni, Gordon, Washington, & Longworth, 1997), LGG 
mitral valve endocarditis (Mackay, Taylor, Kibbler, & Hamilton‐Miller, 1999), LGG 
liver abscess (Rautio et al., 1999), and S. boulardii fungemia complications (Bassetti, 
Frei, & Zimmerli, 1998; Hennequin et al., 2000; Lherm et al., 2002).  However, a decade-
long investigation into the increased use of LGG in Finland demonstrated there was no 
change in the reported cases of Lactobacillus bacteremia despite the 6-fold increase in 
usage over that time period (M. K. Salminen et al., 2002).  Similarly, a study in Sweden 
also found no increased incidence of Lactobacillus bacteremia over a 6-year period 
despite the increased usage of a 3-strain Lactobacillus probiotic supplement (Sullivan & 
Erik Nord, 2006).  Although nearly 100 cases of fungemia associated with S. boulardii 
use have been reported in the literature (Vandenplas, Brunser, & Szajewska, 2009), most 
of these cases have been attributed to GI translocation or through direct bloodstream 
contamination via a central venous catheter from the contaminated hands of healthcare 
workers who first handled the probiotic (Hennequin et al., 2000). 
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Adverse effects such as bacteremia are considered rare, with most cases occurring 
in immunocompromised patients.  For this reason, it is recommended that probiotics not 
be administered to patients who are severely immunocompromised.  It has also been 
proposed that minor risk factors for the development of systemic disease related to 
probiotic use include the presence of a central vein catheter, administration of the 
probiotic through a J tube, an impaired intestinal barrier, and administration in the 
presence of cardiac valvular disease (Boyle et al., 2006), therefore these factors should 
also be taken into consideration.  The manufacturer of Florastor® in particular, warns that 
their product should not be administered to acutely ill patients and capsules should not be 
opened near patients that have a central line (Biocedex Pharma, 2018).  Despite this 
warning, however, S. boulardii has been administered in the acute care setting with great 
frequency.  Caution must be taken to avoid the contamination of the healthcare workers 
hands so as not to contaminate any central venous access device that could cause 
inadvertent administration of the microbe into a patient’s bloodstream.  The two probiotic 
strains to be used in this study are widely commercially available from reputable 
manufacturers and are stable at room temperature with a relatively long shelf-life. 
A recent meta-analysis of randomized controlled trials published between 2004 
and 2007 was conducted by Gu and colleagues (2013) to assess the role that probiotics 
have on the outcomes of trauma patients.  Only five published randomized-controlled 
trials were identified, which furthers the need for more research to be done in this area.  
In this meta-analysis the primary outcome of interest, the incidence of hospital-acquired 
infections, was reduced in the probiotics group (p=0.02).  Secondary outcomes such as 
length of stay were reduced in 2 trials (p<0.001) and the incidence of ventilator-
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associated pneumonia was reduced in 3 of the trials (p=0.01).  In the 5 trials that were 
included, only 2 used the same probiotic strain and one trial used a precursor to probiotics 
(“prebiotic”).  Further, the definition of “nosocomial infection” was only made clear in 3 
of the 5 studies, also true for the definition of “ventilator-associated pneumonia”.   
Given the available research findings in hospitalized patients that suggest 
improved outcomes with probiotic use, the researcher along with physicians in the 
Department of Trauma and Surgery at this 500 bed Level 1 trauma center in South 
Western Pennsylvania have developed and implemented a “Probiotics Protocol” for all 
hospitalized trauma patients meeting inclusion criteria.  This protocol was created based 
on the most current scientific research that has been conducted in trauma and acutely ill 
patient populations.  Consideration was used when making the exclusion criteria for the 
administration of probiotics; high-risk populations that have been identified in case 
reports are excluded from this protocol.  Inclusion and Exclusion criteria are outlined in 
the table below. 
Inclusion Criteria 
 (ANY of the following): 
 
Exclusion criteria  
(do NOT start probiotics if ANY criteria 
met): 
 
o Antibiotic administration 
o Mechanical ventilation 
o Anticipated LOS > 48 hrs 
 
o Age <18 
o Current/recent use 
Immunosuppressive agents:  
o TNF blockers 
o MABs  
o Chemotherapy 
o Chronic corticosteroids 
o Anti-rheumatic drugs 
o Anti-rejection drugs 
o Cardiac valve surgery 
o HIV/AIDS 
o Active malignancy  
o Pregnancy 
Probiotics Protocol:  Inclusion and Exclusion Criteria 
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All patients meeting inclusion criteria were to be given a dual strain of probiotics 
(S. boulardii and LGG) starting within 24 hours of admission and continuing until 
discharge.  Both probiotic preparations are available from the pharmacy in capsule form 
which can be opened and mixed with water for administration via feeding tubes.  
Compliance with this administration was validated through examination of the electronic 
medical record system.   
Theoretical Framework 
 Traditional nursing theoretical frameworks cannot fully describe nor encompass 
the goals of this study.  Although the ultimate goal of this research is to prevent infection 
in hospitalized trauma patients, it involves the administration of a non-FDA-approved 
supplement that must be ordered by a healthcare provider.  In this sense, this study may 
lend itself to more of a “medical” study rather than a nursing one, even though outside of 
the hospital setting, probiotic supplements do not require a prescription.  Prevention of 
infection in the hospital setting requires compliance with established protocols by all 
members of the healthcare team, although these measures often rely heavily on nurses.  In 
this sense, although the probiotic supplement requires a prescriptive order, the goal is to 
reduce infections which certainly impacts nursing.  However, this particular measure 
does not have a robust body of literature that clearly demonstrates the effectiveness and 
absence of harm.  Considering there are no established clinical practice guidelines for the 
administration of probiotics to hospitalized, acutely ill patients, an ethical framework 
surrounding offering “good” and avoiding “harm” seemed most appropriate. 
 In the pursuit of evidence-based practice, there is a certain element of risk that 
must be undertaken when researching new ideas, technologies, and drugs.  This risk, 
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however, must be minimized and every effort should be made to weigh the cost/benefit 
ratio of pursuing new treatments.  “First, do no harm” is an axiom at the root of medical 
and pharmacological education and is used to serve as a reminder to clinicians that every 
medical decision has an element of harm (Smith, 2005).  The goal in medical research is 
to use available knowledge to formulate hypotheses that can be used to potentially 
prevent, treat, or ameliorate illness and disease.  However, as with any new idea, benefits 
must outweigh risks in the absence of true clinical certainness; especially in the case 
where not having enough evidence does not justify inaction.   
When considering different ethical theories, the Precautionary Principle was first 
considered.  This principle places the burden of proof upon the healthcare provider that 
any action taken or activities pursued were reasonably considered to be harmless and 
would most likely provide benefit in the absence of scientific proof.  However, adopting 
the precautionary principle in its strictest form can stifle discovery. At its extreme, the 
principle calls for avoiding risk and the elimination of the use of substances that have not 
been proven to be safe, even if a causal link between the substance and harm has not been 
proven or lacks sufficient evidence (COMEST, 2005). The first manuscript for this 
dissertation was written based on that principle.  After additional thought and research, a 
different guiding framework was ultimately chosen.  The theory of expected utility is a 
normative theory of rational choice which can be applicable in medical decision making.    
 The Expected Utility Theory (EUT) is a theory of how people should make 
decisions and can be useful for medical decision-making when there is a lack of clear 
evidence of efficacy and risk.  Here, the utility of each possible outcome of the action is 
weighted according to the probability that the action will lead to the intended outcome.  
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Based on the calculations of EUT, one can choose the action that will yield the highest 
expected utility.  In other words, the probability of how great the benefit and how bad the 
risk of an action could be is used to guide decision making.  In the case of administering 
probiotics in order to reduce HAIs, the EUT can be used. 
Infection is a leading cause of late death in trauma patients, so prevention of 
infection in trauma patients is paramount.  Potential harms (with every effort made to 
avoid harm) and costs associated with preventative measures clearly are much less than 
those associated with HAIs themselves.  It is only recently that research has been 
conducted on the use of probiotics specifically for the prevention of hospital-acquired-
infections in trauma patients but results are considerably positive.  In the face of such 
limited but promising research, is it reasonable and ethical to use probiotics for the 
prevention of infection in hospitalized trauma patients to improve outcomes? 
Certainly, there is substantial literature to support the overwhelming safety of 
probiotic supplementation but there is a paucity of case studies that suggest a cause-and-
effect relationship between probiotics and septicemia.  However, there is growing 
evidence that probiotics administered to acutely ill patients lead to favorable outcomes.  
Current literature supports that administering probiotics to acutely ill patients is ethically 
justified since the probability of the desired outcome (decrease in infection rates) would 
likely be realized for the greatest number of people. 
Although risks associated with the use of probiotics in hospitalized patients has 
been documented in the literature in the form of case reports, the potential for causing 
harm (namely, the risk of actually causing an infection) has been minimized by excluding 
certain high-risk groups from receiving probiotics.  However, since this risk still exists, 
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expected utility theory will also be used to calculate the probability of this potential 
outcome.  Therefore, researchers can weigh the utility of each possible outcome (HAI, 
infection, antibiotic usage, LOS, mortality, etc.) according to the probability that 
administering probiotics will lead to each outcome.  
    
Research Design and Methods 
Research Design 
This study was conducted using a cross sectional design through retrospective 
medical record review.  The medical records of trauma patients admitted since the 
inception of the probiotics protocol in July 2015 who received the probiotics will 
constitute the intervention group.  The medical records of trauma patients from the year 
prior to implementation of the probiotic protocol (July 2014 through June 2015) as well 
as patient who did not receive probiotics while the protocol was in place will comprise 
the control group.  All data will be reviewed retrospectively extracting variables of 
interest and analyzed using SPSS software (version 25).   
Setting, Population, Sampling Procedures, and Variables 
The researcher, in conjunction with a group of trauma surgeons at the study 
hospital are presently implementing a “probiotic protocol”: all adult (age >18) trauma 
patients admitted to the hospital and meeting certain inclusion criteria are administered 
two strains of probiotics, one containing Lactobacillus rhamnosus GG and the other S. 
boulardii.  The protocol calls for the same strain, dosage, and frequency to be 
administered to each patient, allowing for homogeneity of the treatment.  The probiotics 
protocol began in July 2015 and will continue indefinitely.   Initially, the study design 
was to be a cohort one.  It was anticipated that trauma patients who received probiotics 
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under the probiotics protocol will comprise the intervention cohort and trauma patients in 
the year prior to implementation of the probiotics protocol will serve as the control cohort 
(anticipated to be July 2014 through June 2015).  There will be a group of patients who 
did not receive the probiotics protocol since the protocol was implemented.  Reasons for 
this were discussed earlier.  This group of patients who do not receive the probiotics will 
be evaluated as a third group for statistical purposes.  If this group is not statistically 
different from patients prior to the inception of the protocol and they also did not receive 
the probiotics, then this third group will be combined with the control group for further 
statistical analyses.  Due to difficulty obtaining complete data prior to 2017, the study 
design was changed to a cross-sectional one.  Data from 2017 through June 2018 was 
examined and variables were used for examining associations between probiotic use and 
the outcomes of interest. 
Outcome measures will be compared between the intervention and control groups: 
frequency of infectious complications (pneumonia, BSI/bacteremia, C. diff infection, 
VAP, and urinary tract infection), hospital length of stay, mortality, and duration of 
mechanical ventilation (as applicable, since not all patients will receive mechanical 
ventilation).  In an effort to minimize confounding variables, demographics (age, gender, 
etc.) and Trauma Severity Scores (ISS/AIS) will be reported.  Data on co-morbidities that 
may influence the development of infection will also be collected.  This includes: 
Asthma or Chronic obstructive pulmonary disease (COPD) 
Heart failure (HF) 
Alcohol consumption 
Drug use 
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Diabetes Mellitus (DM) 
Gastro-esophageal reflux disease (GERD) 
High blood pressure (HBP) 
Proton pump inhibitor (PPI) or H2 receptor blocker use (H2RB) 
Hepatic failure 
Renal failure 
History of malignancy 
Operative procedures performed 
Procedures for Data Collection 
After appropriate IRB approval, electronic medical records will be accessed, 
examined, and the demographics and data of interest will be collected.    Additionally, 
descriptive statistics will be run in SPSS looking for outliers.  Data will be stored on an 
encrypted flash drive and kept in a locked, secure location in the researcher’s office.  It is 
anticipated that not all patients who met criteria for receiving probiotics under the 
probiotics protocol actually did.  This is due to many factors including resident turnover 
on the trauma service with lack of communication regarding the institution of the 
protocol and the hospital migrating to a new computer medical record/charting system.  
Due to the latter, the probiotics protocol was not uploaded into the “old” system which 
required that the physicians/resident physicians remember to order the probiotics on the 
paper order form.  Therefore, the researcher anticipates that entire rows of data will be 
missing completely at random.  In this instance, missing data may be handled through 
Regression Substitution whereas a multiple regression analysis will be used to estimate 
any missing values based on existing values.   Another possibility is with the utilization 
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of dummy coding.  This strategy will use all available information about the missing 
observations (received probiotics or not).   
 
 
Plans for Data Analysis  
 Dependent Variables: 
Categorical, dichotomous:  HAIs (yes or no including infection site and 
causative organism), and mortality 
Categorical, interval:  hospital LOS, days of mechanical ventilation 
 Independent Variables: 
Categorical, dichotomous: Probiotics (yes or no including which 
probiotics were received and duration of supplementation), gender, antibiotics 
received (including class, duration, and number of different antibiotics received)  
  Categorical, ordinal: Age, Injury Severity Score (ISS/AIS) 
      Data will be stored in Excel and downloaded into SPSS for Windows (version 25) 
for statistical analyses.  Descriptive statistics will be calculated for the entire sample and 
for individual groups.  Group differences will be tested with chi-square, and Fisher’s 
exact test for numeric and categorical variables, respectively.  Pearson’s correlation test 
will be used to determine associations among variables.  Student’s t test will be used to 
compare the continuous variables between the groups as to whether or not they are 
homogenous (as assessed by the Levene test).  Normality will be assessed using the 
Kolmogorov-Smirnov test and parametric data will be expressed as means, + standard 
deviations, or medians according to the homogeneity of the samples.  P<0.05 will be 
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established as the significance level (type I error).  Incidence rates of infection and 
ventilator-associated pneumonia will be compared using risk ratios (RR) with 95% 
confidence intervals (CI).  Two-tailed power analysis will be done on all end-point 
variables (infection rate, number of infections per patient, hospital length of stay, and 
days spent on mechanical ventilation) with the goal being to achieve at least 80% power 
(type II error).  A priori two-tailed power analysis using an effect size of 0.5 and 0.80 
power shows that approximately 50-60 patients per group (2 groups) will be needed.  
When an effect size of 0.3 is used, sample sizes increased to between 140-180, which is 
not considered feasible given the potential of participants in this hospital setting.  It is 
impossible for the researcher to anticipate the number of patients that will be in each 
group prior to data collection.   
Study Limitations, Potential Problems, Potential Strategies to Address Weaknesses 
     Retrospective studies may not detect rare instances of a disease or phenomenon.  
Therefore, the researcher will need to assess the incidence rates of the outcomes being 
mentioned and calculate a number needed to treat in order to assess the minimum number 
of patients in the study cohort to detect any changes in incidence levels in infections. 
      A second disadvantage is with the quality of the data that is obtained.  The 
researcher has no control over deviations from the probiotics protocol.  There may be 
instances such as patients not receiving probiotics at prescribed times, or initiation of 
administration not occurring within 24 hours over which the research has no control after 
the fact which can affect the outcomes.  There is a great deal of reliance on the record 
keeping of others.  This may have been ameliorated through education of nurses who will 
be caring for these trauma patients and physicians, residents, and nurse practitioners who 
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will be ordering the probiotics protocol.  Attempts to educate resident physicians and 
nurse practitioners (who are responsible for most of the orders for trauma patients) were 
not always successful.   
      Since the outcomes (hospital-acquired infection, days spent on mechanical 
ventilation, LOS and mortality) will have already occurred in the study group, selection 
bias can occur in retrospective studies.  This will be controlled for by including all trauma 
patients.  Until the hospital database is accessed, the researcher cannot determine how 
many trauma patients this will include. 
      Comparability between exposed (probiotics/study group) and non-exposed (no 
probiotics/control group) may be difficult to achieve.  Every effort will be made by the 
researcher to control for confounding variables and assessing homogeneity of the subjects 
through grouping demographics and trauma severity scores within groups.   
 Another issue that may affect data collection is that the researcher will need to 
obtain data from two different medical record systems.  Migration to the new computer 
system occurred in October 2016.  Some patient data from the previous system has been 
carried over to the new system, but at this point in time, the researcher does not know 
how far back this goes. 
     Strengths 
      This retrospective study will allow for the calculation of the incidence of multiple 
outcomes in the study (probiotics) group.  Not only will the researcher be able to 
calculate absolute risk (incidence), for relative risk, risk difference, and attributable 
proportion (attributable risk %) of hospital-acquired infection, mechanical ventilation 
days, and length of stay can be calculated as well.     
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      One major strength of this study design is that it is good for studying multiple 
outcomes.  The outcome of hospital-acquired infections will have 4 subgroups 
(ventilator-associated pneumonia for mechanically ventilated patients, central line 
associated infections, urinary tract infections, and Clostridium difficile infections) as well 
as the outcome of length of stay and days of mechanical ventilation (as applicable). 
      Retrospective studies also are relatively inexpensive as the outcome and exposure 
have already occurred.  They are also rather quick to perform, the only time needed is for 
data collection on existing data sets and time for statistical analyses and interpretation. 
Plan for Dissemination of Results 
      The researcher intends to disseminate findings through peer-reviewed trauma 
journals and at educational venues and conferences.  This study also will be presented at 
the Keystone Trauma and Research symposium and will be submitted to the 
Pennsylvania Trauma Society in partial fulfillment of accreditation standards for Level I 
trauma status for Conemaugh Memorial Medical Center in Johnstown, Pennsylvania.  
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Appendix A 
Probiotic Administration Protocol 
For all at-risk adult trauma patients 
(unless any 1 or more exclusion criteria exists) 
Inclusion Criteria (ANY of the following): 
o Antibiotic administration 
o Mechanical ventilation 
o Anticipated LOS > 48 hrs 
Exclusion criteria (do NOT start probiotics if ANY criteria met): 
o Age <18 
o Current/recent use Immunosuppressive agents:  
o TNF blockers 
o MABs  
o Chemotherapy 
o Chronic corticosteroids 
o Anti-rheumatic drugs 
o Anti-rejection drugs 
o Cardiac valve surgery 
o HIV/AIDS 
o Active malignancy  
o Pregnancy 
Probiotics should be started as soon as inclusion criteria met and continued throughout 
hospitalization: 
___ Florastor 250mg po/NGT/CP/PEG/J tube BID 
  AND 
___ Culturelle 1 tablet po/NGT/CP/PEG/J tube once daily 
If infection suspected, discontinue both probiotics and order: 
 Routine sputum culture and Fungal sputum culture 
 Blood cultures X 2 set 
 Urine culture  
 
Physician signature: _____________________________________ 
Date/Time:_____________ 
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Chapter 4 
 
This chapter contains 3 manuscripts:  
 
1.  A manuscript that is currently under revision 
 
2.  A manuscript that has been accepted and will publish early in 2019 
 
3.  A final manuscript describing the research study, findings, and conclusions.  
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Probiotics: Help or Hype?  Can probiotics prevent infection in trauma patients? 
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Abstract 
There is increasing interest in the use of probiotics in the acute care setting for prevention 
and treatment of infection.  Although several studies with probiotics have been conducted 
over the past decade that show clinical efficacy and safety, there is a clear lack of 
homogeneity in these studies with respect to species and strain selection, timing of 
initiation and duration of probiotic administration, and dosages.  Outcomes generally 
studied include prevention and treatment of Clostridium difficile infections, prevention of 
ventilator-associated pneumonia, and other healthcare-acquired infections.  Research in 
the use of probiotics in the trauma population to prevent infection in increasing.  
Although the role of probiotic administration in trauma patients remains unclear, 
published research is quite promising.  However, the results of these studies must be 
interpreted cautiously due to several limitations. 
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Introduction 
As the use of probiotics increases throughout the healthcare system for the 
prevention of infection, it is of importance that all healthcare clinicians understand the 
benefits and the risks of using probiotics in acutely ill patients.  The purpose of this 
article is to provide the current state of the research regarding use of probiotics in the 
acute care setting, particularly in the trauma population, to prevent infection and improve 
outcomes.  Benefits of the use of probiotic supplementation as well limitations to current 
research will be presented so that healthcare providers can better interpret the evidence 
that exists both for and against probiotic use in the hospital setting. 
The Human Microbiome 
What we once referred to as “normal flora” is now being termed the “human 
microbiome,” the intactness or breakdown of which influences our physiology and our 
susceptibility to disease and illness (Jacobs, Haak, Hugenholtz, & Wiersinga, 2017; 
Stavrou & Kotzampassi, 2017; Young, 2017).  The resident organisms that comprise the 
microbiome serve as ecological, mechanical, and immune barriers  (Fasano & Shea-
Donohue, 2005; Fawzy, Genena, & Sewify, 2017).  The intestines and the resident 
microbiota, which are comprised of trillions of living species of bacteria, archea, fungi, 
and viruses are important parts of the human immune system.  The resident microbiota 
are responsible for maintaining barrier function which serves to keep the non-pathogenic 
“friendly” bacteria in and diminishes the possibility for pathogenic bacteria to translocate 
and cause disease  (Preidis & Versalovic, 2009).  The microbiome also serves as a part of 
our innate and adaptive immunity.  Although the microbiome is present at birth, it is 
constantly developing and changing with the introduction of things we ingest such as 
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foods and medications (G. D. Wu et al., 2011; H. Wu, Tremaroli, & Bäckhed, 2015).  An 
individual’s microbiota are constantly being shaped by the hosts’ genetics, environmental 
exposures (Jonkers, 2016), diet, host factors, and events or substances, all of which may 
disrupt this complex host-microbe interaction (Fishman & Thomson, 2015).  Disruption 
of the microbiome of an individual can decrease one’s host defenses and cause increased 
susceptibility to infection and disease. 
Trauma and the Microbiome 
Traumatic injury is one of those events that can alter our microbiome in many 
ways.  Infection and sepsis is a leading cause of late death in trauma patients (Lenz, 
Franklin, & Cheadle, 2007; Lord et al., 2014; Morgan, 1992), therefore prevention of 
infection is paramount in this population.  Mechanisms of traumatic injury cause 
immunological dysfunction and hyper-inflammatory responses that can alter immune 
function and significantly affect morbidity and mortality (Akrami & Sweeney, 2018; 
Howard et al., 2017).     
The host response to traumatic injury and related tissue damage involves a 
cascade of inflammatory mediator responses that places these patients at risk for 
secondary infections and complications of the inflammatory response (Stoecklein, Osuka, 
& Lederer, 2012).  This immune dysfunction can lead to a concept known as “immune 
paralysis” which increases the risk for the development of sepsis and multiple organ 
dysfunction which may lead to death (Hietbrink et al., 2006; Lenz et al., 2007).  Further, 
a study performed by Menges and colleagues (1999) found that patients with severe 
trauma exhibit a marked depression in immunity characterized by an increase in cytotoxic 
T cells and a decline in helper lymphocytes.  This multi-organ dysfunction, a syndrome 
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known as “MODS”, involves multiple mediators involved with the inflammatory 
response – most notably pro-inflammatory cytokines (Desborough, 2000; Lenz et al., 
2007; Oberbeck, 2006).  This non-specific inflammatory and immune response causes the 
release of mediators that can also disturb normal gastrointestinal flora and impair barrier 
function, contributing to translocation of intestinal microbiota.  The result of this 
dysfunction is that normally non-pathogenic intestinal GI flora can migrate and become 
pathogenic in other areas of the body.   
The procedures and medications that are utilized in caring for the trauma patient 
can add further insult to the injurious events caused by trauma.  For mechanically 
ventilated patients and those in the Intensive Care Unit, these further insults can be 
numerous. 
Adding Insult to Injury 
     The cascade of inflammatory reactions that is set off by a traumatic injury is 
intended to boost the immune defenses of the host; the greater the extent of the trauma, 
the greater the degree of inflammation.  This inflammatory process, however, can lead to 
immune dysfunction which serves to actually place the patient at greater risk for the 
development of secondary infection and complications of the inflammatory process (Lord 
et al., 2014; Stoecklein et al., 2012).  Additionally, treatments that are common practice 
for traumatically-injured patients can further compromise a patient’s immune defenses.  
Hospital-associated infections are leading causes of mortality, morbidity, and 
increased financial burden (Glance, Stone, Mukamel, & Dick, 2011).  Things that we do 
to our patients in the hospital, from invasive procedures to treatment modalities and even 
medications, can disrupt not only the mechanical barriers that prevent infection but the 
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biological defense mechanisms as well (Rijkers, 2011).  Patients who survive an initial 
injury or disease process still may die as a result of the subsequent immune reactions that 
are induced by the event itself due to immunological dysfunction and hyper-
inflammatory responses that can alter immune function.   
Invasive Procedures 
Invasive procedures can also disturb a person’s natural barriers to infection.  
Central venous access lines are often necessary, as are indwelling foley catheters.  These 
can serve as an entry point for pathogenic bacteria.  Additionally, endotracheal intubation 
can lead to ventilator-associated pneumonia.  Trauma patients often undergo surgical 
procedures, sometimes more than just once.  
Stress Ulcer Prophylaxis 
Ventilator bundle of care, considered best practice for patients receiving 
mechanical ventilation, includes the use of peptic ulcer disease prophylaxis which can be 
in the form of H2 receptor blockers (H2RBs) or proton pump inhibitors (PPIs) (Neuville, 
Mourvillier, Bouadma, & Timsit, 2017).  According to a recent observational multi-
center study, PPIs are the most widely used off-label medication in the ICU, with “stress 
ulcer prophylaxis” being cited as the most common indication for use (Barletta et al., 
2015).  The composition of human intestinal flora is influenced by gastric acid; the acidic 
environment of the stomach normally functions as a barrier to prevent GI flora from 
translocating and causing infection (Beasley, Koltz, Lambert, Fierer, & Dunn, 2015).  
Additionally, since the administration of PPIs and H2RBs raise the gastric pH, certain 
enteric pathogens can thrive in this less acidic environment, most notably some strains of 
Escherichia coli and Clostridium difficile (Bavishi & Dupont, 2011).  Infections such as 
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pneumonia, enteric infections, and bacterial gastroenteritis have also been linked with 
increasing intestinal pH through the use of PPIs (Kanno et al., 2009; Yang & Metz, 
2010).  A study by Thorens et al. (1996) found that 53% of patients treated with 
omeprazole developed bacterial overgrowth explained by pronounced inhibition of 
gastric secretion.  Histamine also plays many roles in the human body including the 
regulation of several components of the immune response (Jutel, Akdis, & Akdis, 2009). 
Thus, H2 receptor blockade can negatively affect immune response.   
Catecholamines and Vasoactives 
     Catecholamines are released as part of the stress response.  The 
immunomodulatory effect that catecholamines have in the body were first documented 
over 100 years ago; recent studies demonstrate the effects that these catecholamines have 
on a person’s cellular immune function and peripheral immune system.  Catecholamines 
lead to the release of pro-inflammatory cytokines (Desborough, 2000; Lenz et al., 2007; 
Oberbeck, 2006).  Although the release of these chemical mediators occurs naturally, 
secondary to a traumatic event, synthetic catecholamines are often administered to these 
patients as well.  Epinephrine, norepinephrine and dopamine, commonly referred to as 
vasopressors when utilized in the clinical setting, are used in the trauma population to 
support blood pressure during times of hypotension or other reasons where a higher mean 
arterial pressure is clinically warranted.   
The Effects of Antibiotics on the Microbiome  
Antibiotics, although life-saving, are a major cause of disruption of the human 
microbiome which can lead to antibiotic-associated diarrhea and Clostridium difficile 
(C.diff) infection, both of which are leading causes of morbidity and mortality in 
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critically ill patients (McDonald et al., 2018).  More than half of all hospitalized patients 
receive at least one dose of antibiotics (Baggs, Fridkin, Pollack, Srinivasan, & Jernigan, 
2016). Even a single dose of an antibiotic can alter the microbiota enough to allow C. diff 
to cause infection (Buffie et al., 2012), and even short term antibiotic usage can alter the 
intestinal microbiome for up to 24 months (Stavrou & Kotzampassi, 2017).  Although the 
purpose of antibiotic administration is to treat infection by eradicating pathogenic 
bacteria, they kill the “good” bacteria as well, affecting our GI immune defenses.  An 
overgrowth of pathogenic bacteria is then able to grow and flourish. 
Endogenous and Exogenous Opioids 
 Morphine is endogenously-produced in people during the inflammatory response.  
It, along with other opioids, is also administered exogenously for the purpose of analgesia 
and sedation in critical care settings, those with traumatic injuries, and those undergoing 
surgical procedures (Mora et al., 2012).  Morphine is a powerful immunosuppressant that 
also slows down gut motility, delaying transport time which potentially increases the risk 
for translocation of bacteria across the intestinal wall (Balzan, de Almeida Quadros, De 
Cleva, Zilberstein, & Cecconello, 2007).  Researchers have also determined that chronic 
morphine use significantly alters the composition of the gut microbiota allowing rapid 
growth of gram positive pathogens (Banerjee et al., 2016). 
The Importance of Prevention 
In a study based on the Healthcare Cost and Utilization Project Nationwide 
Inpatient Sample, researchers found that trauma patients (n=155,91 records reviewed) 
who incurred a healthcare-associated infection (HAI) such as sepsis, pneumonia, 
infection with staphylococcus or Clostridium difficile-associated disease, experienced 
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greater hospital length of stays, increased mortality and costs associated with care 
(Glance et al., 2011).  Specifically, trauma patients who developed sepsis had a 6-fold 
higher odds of dying than those who did not become septic (p<.001).  Trauma patients 
with other HAIs not characterized as sepsis still had a 1.5-1.9 fold higher odds of 
mortality than those who did not develop an HAI (p<.005).  For the non-HAI group, costs 
were significantly lower (p<.001) as was length of stay (p<.001).  This study further 
supports the need to prevent HAIs in the trauma population. 
Restoring the Microbiome with Probiotics 
Probiotics are non-pathogenic “friendly” bacteria.  Mostly used by healthy people 
to restore or maintain GI health, recent studies have provided some insight into just how 
probiotics can affect our microbiota and regulate colonization of pathogens in the gut 
(Kitazawa et al., 2015; Williams et al., 2010).  The use of probiotics has been used for 
more than a century, usually in the form of fermented foods, in fact even Hippocrates 
acknowledged the importance of our GI tract in preventing disease; and how important it 
is to maintaining a healthy gut.  “Death sits in the bowels, a bad digestion is the root of 
all evil” (Hippocrates, ca. 400 BC).  However, it was not until the late 1900’s that 
researchers suggested that “bad” bacteria could be replaced with “good” bacteria in the 
gut and, hence, the concept of probiotics was formed (FAO/WHO, 2001; Schrezenmeir & 
de Vrese, 2001).   
Use of probiotic supplements in the acute care setting is gaining worldwide 
attention, but their clinical effectiveness is not entirely clear.  The administration of these 
living organisms is used to re-establish normal non-pathogenic human microflora and 
prevent sequelae involving the disruption of our human gut microbiome.  Probiotics 
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restore the balance of normal gut microbiota, which inhibits bacterial translocation and 
decreases pathogenic bacteria that emit inflammatory toxins, which then in turn restores 
proper immune function.  There is considerable evidence that certain strains of probiotics, 
when ingested in adequate amounts, demonstrate both anti-inflammatory and anti-
pathogenic effects for the host offering promise for the use to both prevent and treat 
certain diseases (Isolauri et al., 2001).   
The use of probiotics in the acute care setting has steadily increased over the past 
10 years.  A descriptive study examined the discharge records of nearly 2 million patients 
in 2012 in a sample of 145 US hospitals (Sarah, Jernigan, & McDonald, 2016).  During 
that year, more than 50,000 (2.6%) patients in 96% of those hospitals received probiotics.  
Although this may not seem like a large number, this study revealed that probiotic usage 
in hospitalized patients tripled between 2006 and 2012.  The question that remain, 
however, is what strain of probiotic is best for which condition and at what dosage and 
duration? 
Current Research with Probiotics 
Clostridium difficile-Associated Diarrhea (CDAD) 
Perhaps the strongest evidence supporting the use of probiotics is for the 
prevention and treatment of antibiotic associated diarrhea and Clostridium difficile 
infections.  A recent meta-analysis examined 26 RCTs involving 7,957 patients 
(Chamberlain & Lau, 2016).  Probiotic use reduced the risk of the development of CDAD 
by 60.5%, especially among hospitalized patients; adults and children alike.  
Lactobacillus, Saccharomyces (a yeast) and a mixture of probiotics were all beneficial in 
reducing risk (63.7%, 58.5%, and 58.2% respectively).   
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Even more recent, a retrospective review of patients admitted with a traumatic 
injury between 2008 and 2014 who received antibiotics (N=4632) found that the 
implementation of a C. diff bundle, which included the administration of probiotics, 
significantly reduced the incidence of CDI infection (Bommiasamy et al., 2018).  The 
form of probiotics used in this hospital included Nancy’s yogurt ™ (Springfield 
Creamery, Eugene, Oregon) and kefir, which contain a combination of 4 strains of 
Lactobacillus, Bifidobacterium lactis, and Streptococcus thermophilus.  Although 
components of this bundle were initiated in a step-wise fashion, CDI rates among patients 
started to decline once probiotic administration was implemented and prior to every 
component of the bundle was enacted (Bommiasamy et al., 2018).   This study also 
reported that no adverse effects, including clinical infection, occurred as a result of the 
use of probiotics. 
Ventilator-Associated Pneumonia (VAP) 
A recent meta-analysis that included 13 random control trials (RCTs) and 1,969 
patients found that the administration of probiotics was associated with a lower incidence 
of VAP (p=0.002) (Weng et al., 2017).  The authors concluded that it is likely that 
probiotics offer some benefits for mechanically ventilated patients.   
Hospital-Acquired Infections 
Gu and colleagues (W.-J. Gu, T. Deng, Y.-Z. Gong, R. Jing, & J.-C. Liu, 2013) 
conducted a meta-analysis of RCTs published between 2004 and 2007 and concluded that 
the incidence of HAIs were reduced in trauma patients who received probiotics as part of 
early enteral nutrition (p=0.02). Again in 2016, a meta-analysis of 33 RCTs which 
included 2,972 patients showed that the administration of probiotics to critically ill 
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trauma patients resulted in a significant reduction in overall infections (Kotzampassi, 
Giamarellos-Bourboulis, Voudouris, Kazamias, & Eleftheriadis, 2006). 
Regulation of Probiotics 
Commercially prepared probiotics are considered a “supplement” or “medical 
food” and therefore not regulated by the FDA.  This means that once the probiotic 
preparation leaves the manufacturer, there is no control over quality, viability, or content.  
Independent studies have been conducted that show the composition of microbes in 
several commercially prepared probiotic supplements are not what is written on the label 
(Huys et al., 2006).  This can contribute greatly to inconsistencies in outcomes and 
further lead to a lack of homogeneity in studies; even when the same brand of probiotic is 
used. 
Safety of Probiotic Supplements 
     While the majority of existing evidence suggests that probiotics are safe, 
serious adverse events associated with probiotics, although rare, have been reported 
(Doron & Snydman, 2015).  At risk populations include immunocompromised patients, 
patients with pancreatitis, and patients with mechanical heart valves although other 
patient populations have been reported to experience adverse events.  Risk-benefit ratios 
should be weighed when considering use in at-risk patients. (Didari, Solki, Mozaffari, 
Nikfar, & Abdollahi, 2014).  While there are many studies that examine the efficacy of 
probiotics for the prevention and treatment of a variety of conditions, there are few 
studies that have specifically examined the safety of these supplements when used in the 
acute care setting. 
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     Although probiotic organisms are naturally-occurring commensal bacteria 
present in the human microbiome, the safety of administration of manufactured probiotic 
organisms to acutely ill hospitalized patients has been questioned.  There are published 
case reports of probiotic supplementation potentially being associated with fungemia 
(Thygesen, Glerup, & Tarp, 2012), bacteremia (M. K. Salminen et al., 2004), and sepsis 
but these are relatively few (S. Hempel et al., 2011).  Mostly these case reports are 
anecdotal and considered by some to be negligible in numbers when compared with the 
large number of patients who are given probiotic supplements each day.  Others may 
argue that adverse events related to probiotic supplementation may not be recognized or 
reported in the literature therefore infection caused by probiotics may be grossly under-
acknowledged.  Hempel et al (2011) evaluated 622 intervention studies that addressed the 
safety of probiotic supplements since August 2010.  They concluded that while the 
intervention studies do not indicate an increased risk of adverse events, they found that 
there is not a structured system for assessing and reporting untoward events which could 
contribute to the rarity of adverse events in the literature.  Only 387 of these studies 
specifically reported the presence or absence of adverse events, but these events were 
poorly documented.  Therefore, in certain patient populations, a precautionary approach 
must be taken (Vitko, Sekula, & Schreiber, 2017). 
No Clear Clinical Practice Guidelines 
Although research supports benefits to the administration of probiotics in trauma 
patients, many limitations to that research exist.  Differences in probiotic species, dosing, 
timing, and duration cause significant heterogeneity in these studies.  Systematic reviews 
of the published literature, therefore, cannot yield a true meta-analysis due to the lack of 
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homogeneity in studies.  Of the meta-analyses presented here, few studies used the same 
strain, dosage, and duration. 
Although varying results in outcomes with the use of probiotics may be due to 
these differences, another aspect that must be considered is the viability of the probiotic 
preparation itself.  Probiotics are living organisms that generally are sensitive to heat and 
pH extremes.  In studies where a probiotic supplement has not been shown to be 
efficacious, one must consider not only the aforementioned limitation, but consider the 
viability of the probiotic organisms themselves as they reach the intestines.  This is not 
only a consideration once the probiotic is ingested, but proper handling and storage on 
the shelf should be considered as well. 
Other limitations to published studies include the number of participants that is 
necessary in order to achieve statistical significance and meet intent-to-treat numbers.  
Most studies have small sample sizes which render them underpowered.  Further, few 
studies included what clinical definition was being used for ventilator-associated 
pneumonia, since at the time of the studies there was not a standardized and universal 
clinical diagnostic criterion set for the diagnosis.  Next, HAIs were often grouped 
together, with few studies actually reporting just what infection was present in the 
patient.  Severity of traumatic injury certainly has an effect on outcomes as well; there 
lacked consistency on how severity was measured which can affect outcome 
measurement.  More severely injured or multi-injury patients are generally at greater risk 
for immune dysfunction and increased infection rates. 
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Conclusions and Implications for Future Research 
     The use of probiotics in the acute care setting is increasing, yet there remain 
relatively few high-quality RCTs that have specifically examined probiotic role in the 
trauma population.  Further, meta-analyses of existing RCTs that pooled results from 
trials using probiotics to prevent different diseases are flawed.  Since the research into 
probiotic use is relatively new and there is a clear lack of homogeneity in published trials, 
one must cautiously interpret results from pooled estimates of risk where different types 
of probiotic strains, dosages, durations, etc. have been used to derive findings (L. V. 
McFarland, 2015).  Further, effects of probiotics may be strain and species specific, 
meaning that findings of one study demonstrating effectiveness of a particular species 
may not be applicable to other conditions.  Caution must be taken with attempts to 
generalize findings, even within similar strains.  For example, there are 11 Lactobacillus 
species and 7 Bifidobacterium species currently known (Senok, Ismaeel, & Botta, 2005).  
In order for clinical practice guidelines to be developed, there must be greater 
homogeneity in studies with larger multi-center randomized-controlled trials being 
conducted with the trauma population.  Additionally, definitions of infections/clinical 
diagnostic criteria should be standardized as well as utilization of the same trauma 
severity scoring systems in order to better generalize findings. 
Implications of Key Findings 
     Although one cannot clearly conclude that probiotic supplementation in the 
trauma population should be used to improve outcomes such as decreased infection rate, 
ventilator-associated pneumonias, mechanical ventilator days, decreased antibiotic usage, 
decreased hospital and ICU length of stay, morbidity, and mortality, the current evidence 
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strongly suggests that probiotics positively contribute to these outcomes with relatively 
low risk in most patients.  Until more rigorous research is performed using the same 
strains, dosages, and timing of probiotic administration, it may be reasonable to use 
current research for the use of probiotics in this population as benefit seems to be likely. 
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Probiotics in the critical care unit: fad, fact, or fiction? 
Abstract: The gut microbiome consists of normally non-pathogenic bacteria, viruses, and 
fungi. These friendly microbes serve to maintain gastrointestinal (GI) barrier function and 
integrity, play a role in host nutrient and drug metabolism, immunomodulation, and 
prevent pathogenic bacteria from colonizing or causing disease. Healthy people have 
used probiotics for centuries to promote and restore GI health by restoring the normal 
flora. Probiotics continue to captivate consumers in the current health conscious society 
for their provocative health claims. The importance of a healthy microbiome for the 
overall health of the host is just recently being appreciated within the medical and science 
communities, however. Disruption of the microbiome places one at greater risk for illness 
and infection. Critically ill patients are among those at highest risk for complications 
associated with microbial imbalance, or dysbiosis. Patients being cared for in intensive 
care units are subjected to a variety of treatments and therapies that account for a 
tendency toward dysbiosis. These include treatment with antibiotics, proton pump 
inhibitors, and opioids as well as therapies that require invasive procedures and 
monitoring. With the consequential compromise to one’s immunity, critically ill patients 
are at the greatest risk for healthcare-associated infections (HAIs). One suggested means 
to restore immune function and for the prevention of HAIs is to supplement patients with 
probiotics. Probiotics may serve to prevent and ameliorate the effects of a number of 
HAIs, including: ventilator associated pneumonia (VAP), Clostridium difficile infection 
(CDI), catheter-associated urinary tract infection (CAUTI), and surgical-site infection 
(SSI). Despite promising findings regarding the efficacy of probiotics for a number of 
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conditions, supplementation with probiotics is not without risks. Consumers and 
prescribers must be educated on what probiotics can and cannot do and should 
understand that not all probiotics are the same. 
Keywords: Probiotics; critical illness; cross infection; microbiota 
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Introduction 
Probiotics, mostly in their “natural” form, have been used by otherwise healthy people 
to promote and restore gastrointestinal (GI) health. The term “probiotics” is not new; 
in fact, probiotics have been around for centuries, mostly consumed in the form of 
fermented food for the associated lenitive effects. Probiotics are the normally non-
pathogenic bacteria, viruses, and fungi that reside in one’s GI tract. These friendly 
microbes make up the human GI microbiome, or flora, and serve to maintain GI 
barrier function and integrity, play a role in host nutrient and drug metabolism, 
immunomodulation, and prevent pathogenic bacteria from colonizing or causing 
disease. The importance of a healthy microbiome for the overall health of the host is 
just recently being appreciated within the medical and science communities. 
It is widely known that healthy GI flora is important for overall health of the host, and 
the disruption of this leaves one with increased susceptibility to illness and disease. 
Here we will provide an overview of the current understanding of the human 
microbiome, alterations caused to it by critical illness and associated 
procedures/therapies, and the use of probiotics to restore GI flora for the prevention 
and amelioration of infection. 
 
Function of the microbiome 
Long before existence of microorganisms was known, fermented products were used 
therapeutically to treat a number of ailments, including fevers, the common cold, and 
GI distress (nausea and diarrhea). It is now understood that this “normal flora” is part 
of one’s natural defense against pathogenic invaders. The entire human microbiome 
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consists of viruses, bacteria, fungi, archaea, and single-celled eukaryotes (1). In fact, 
it is estimated that there are more than 100 trillion bacterial cells comprised of more 
than 35,000 species that constitute our microbiome (2). Most of these organisms are 
naturally found in the GI tract, yet others exist as part of the respiratory or 
genitourinary tract as well as upon our integument (3). Although the healthy gut 
microbiota consists of varying species and numbers throughout the entire GI tract, 
nearly 75% of the microbes exist within the large intestine alone (4). When discussing 
illness or disease related to disruption of the GI flora, it is generally referring to 
colonic bacteria, and these bacteria usually are what are trying to be restored. 
Even ancestral scholars acknowledged the importance of maintaining a healthy GI 
tract in preventing disease. As early as 400 BC, Hippocrates asserted “death sits in the 
bowels… a bad digestion is the root of all evil”. The mechanism through which a 
healthy gut augments one’s immunity is complex and multifaceted, but it can be 
understood through three barriers of immunity.  
The first barrier is the ecological barrier, which is the inhabitant flora of our 
intestines. The second mechanical barrier resides at the cellular level; it is the intact 
mucosal epithelia that form a direct, physical barrier against pathogenic organism 
invasion or translocation of otherwise harmless resident bacteria. The third barrier is 
an immune barrier, comprised of a slew of host immune cells, including 
intraepithelial lymphocytes, macrophages, neutrophils, natural killer (NK) cells, 
aggregated mesenteric lymph nodes (Peyer’s patches) and immunoglobulin A.  
Disruption of any of these barriers will often have nocuous consequences (5).  
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As aforementioned, the ecological barrier consists of the trillions of “good” viruses, 
bacteria, and fungi residing in the human body. Some of the most prevalent and 
commonly supplemented organisms harbored in the GI tract are of the 
Bifidobacterium and Lactobacillus species. More specifically, these include strands 
Bifidobacterium animalis, Bifidobacterium infantis, Bifidobacterium lactis, 
Lactobacillus casei, Lactobacillus rhamnosus GG, Lactobacillus reuteri, and the 
yeast Saccharomyces boulardii (6). While each strand 
of species confers upon the host its own immunologic and nonimmunologic benefits, 
these organisms collectively modulate a healthy gut and immune system through a 
variety of similar means. Most importantly, these resident organisms compete against 
pathogens for binding sites and nutrients utilized as growth substrates (7). 
Additionally, these friendly organisms produce vitamins (B, K) that can be used for 
growth of other non-pathogenic organisms, exert anti-inflammatory effects through 
increasing or decreasing certain cytokine and interleukin activity (8), and stimulating 
an innate immune response through activation of helper-T cells, macrophages, NK 
cells, and immunoglobulins (4).  
The normal flora also influences the maintenance of mechanical barrier function—the 
second barrier. When this mechanical barrier of epithelial cells is disrupted, 
pathogens as well as bacteria which exert no harmful effect inside the GI tract can 
translocate and cause disease elsewhere. The breakdown of the GI barrier has been 
linked to several diseases, including: inflammatory bowel disease, chronic kidney 
disease, necrotizing pancreatitis, celiac disease, food allergy, Clostridium difficile 
infection (CDI), and sepsis (3,9).  
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Breakdown and disruption of the GI flora derives from a number of processes, 
including dehydration and malnutrition, but also may be inadvertently incurred 
through the administration of antibiotics and other pharmacological therapies (10). 
The resulting microbial imbalance, or dysbiosis, in turn, affects the third barrier of 
defense by altering levels of host immune mediators while inducing both chronic 
inflammation and metabolic dysfunction. What’s more, the composition of the gut 
microbiome is influenced by various environmental factors, such as lifestyle, diet and 
hygiene preferences as well as the physiological effects of traumatic injury and 
critical illness (4,11). Additionally, the procedures and medical therapies that patients 
are subjected to during hospitalization can further disrupt the GI flora, making a 
patient even more susceptible to infection. Each of these influences will be discussed 
in more detail later. 
The effect of enteral nutrition on the microbiome 
It is understood that a variety of inherent host factors influence the composition and 
integrity of the microbiome. Perhaps the most important of these is the host’s enteral 
nutrition, or diet; for, dietary and bacterial metabolites influence immune responses 
and gut microbiome physiology (12). Therefore, nutritional strategies directed at 
restoring the natural flora may have particular utility in the critically ill, given that 
these individuals are most susceptible to alterations of the microbiome. Most of the 
research has focused on the role fats, carbohydrates, and protein have on gut 
microbial composition (13). However, greater intake of fiber is thought to strengthen 
the intestinal barrier, increase peristalsis, and reduce gut inflammation (14).  
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Fiber, once consumed, is fermented to short chain fatty acids, which include acetate 
and butyrate. These fatty acids bind G-protein-coupled receptors (GPR43, GPR41), 
which foster homeostasis and the regulation of inflammatory responses in the gut. 
More specifically, the G-proteincoupled receptors bound to metabolites augment 
epithelial integrity and IgA antibody responses (12). Conversely, enteral antibiotic 
intake may disrupt gut and immune homeostasis by altering the encompassed short-
chain fatty acid metabolites, consequently promoting the inflammatory status of the 
intestinal mucosa (15).  
Adapting diets specific to patient needs, including supplementation with probiotics, 
prebiotics and synbiotics, are possible nutritional strategies for improving gut and 
microbiome homeostasis. Prebiotics, which are often found as complex carbohydrates 
in fruits, vegetables and grains, are undigested and unabsorbed until reaching the 
large intestine where selective fermentation occurs.  This promotes the growth and 
metabolic activity of host flora, which further promotes gut-barrier homeostasis. 
Probiotics, as previously discussed, may inhibit the growth of enteric pathogens 
through completive exclusion. They also interact with resident microbiota to 
modulate host immune function (14).  
Critical illness and infection prevention  
Increased risk 
Patients in critical care units constitute a small percentage of total hospital 
admissions, yet they account for approximately 25% of all healthcare-associated 
infections (HAIs) (16).  
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Infection as a complication of critical illness contributes to increased ICU length of 
stay (LOS), costs associated with admission, resistance to antimicrobials, and 
morbidity and mortality (17). HAIs are those infections not present and without 
evidence of incubation at time of admission but develop or become clinically evident 
after 48 hours of admission. According to the CDC and the results of the 2014 HAI 
Prevalence Survey, a total of 722,000 HAIs were documented in U.S. acute care 
hospitals in 2011. What’s more, an astonishing 75,000 patients died as a result of 
these infections (18). The five most prevalent HAIs were: surgical-site infection 
(SSI), ventilator-associated pneumonia (VAP), CDI, central-line-associated 
bloodstream infection (CLABSI), and catheter-associated urinary tract infection 
(CAUTI) (19). The role that probiotics may play in post-surgery infections, VAP, and 
CDI will be discussed here. The limited information on CAUTI prevention will also 
be discussed. The reasons that patients in critical care units incur more infections are 
many, but the pure nature of critical illness as well as the multitude of treatment 
modalities necessary for care are major factors. 
Disruption of our innate barrier defense mechanisms 
The physical barriers afforded by our innate immune response such as skin and the 
mucosal lining of our respiratory, GI, and urinary tract, can be disrupted either by 
injury or from procedures common in the critical care unit. Skin barriers are breached 
by intravenous lines and surgical procedures. Respiratory barriers are compromised 
by endotracheal intubation. Gastric tubes, inserted nasally or orally, as well as 
indwelling urinary catheters can disrupt mucosal barriers within our GI/GU systems. 
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Endogenous insult also occurs, perpetrated by certain medications and procedures. 
All of these serve as means to treat illness, injury, and disease, yet at the same time 
have infelicitous and puissant consequences. 
Common pharmaceutical treatments that alter the microbiota 
Antibiotics 
It is widely understood and accepted that antibiotics have bactericidal and 
bacteriostatic effects against both pathogenic and non-pathogenic “good” bacteria. 
These effects include major changes in the gut microbiota taxonomic diversity which 
accounts for decreased ability for competitive exclusion. That is, antibiotics destroy 
multitudes of good bacteria that allow pathogenic bacteria to survive due to less 
competition for binding sites and growth substrates. However, of principal concern 
regarding the use of broad-spectrum antibiotics is the opportunity for resistant strains 
to emerge and be promulgated through horizontal gene transfer among surviving 
organisms. This accounts for a two-fold insult to human hosts; for, not only are hosts 
experiencing an alteration of the normal gut microbial diversity, but also pathogenic 
microbes are being adapted to survive against the current best means for 
eradication—antimicrobial therapy (4).  
It is estimated that more than half of all hospitalized patients received at least one 
antibiotic during their stay (20). Research demonstrates how GI flora destroyed by 
just one dose of an antibiotic often takes months to years to recover and host flora 
may never return to a pre-antibiotic state (21). Further, one-third of antibiotics 
prescribed in U.S. hospitals involve prescribing problems including prescribing 
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antibiotics for a patient who is not clinically indicated (22). With an understanding of 
antibiotic-induced dysbiosis, it becomes important for clinicians to focus their efforts 
on preventing infection and treating HAIs with non-antibiotic strategies whenever 
possible. Probiotic administration is just one of the suggested strategies for 
accomplishing this. 
H2 receptor blockers/proton pump inhibitors 
Prevention of stress-induced ulceration of the GI mucosa is quite common in 
intensive care units. Usually this is achieved through pharmacological measures such 
as the administration of H2 receptor blockers and proton-pump inhibitors. Although 
they offer GI protective effects, the acid secretion suppression and neutralization of 
GI acidity can be hospitable for a number of pathogenic organisms to flourish, 
namely Escherichia coli and Clostridium difficile (CD) (23). Other infections 
associated with an increase in gastric pH and subsequent bacterial overgrowth include 
pneumonia and bacterial gastroenteritis (24). 
Catecholamines 
In times of critical illness and stress, the adrenal glands secrete glucocorticoids from 
the cortex and catecholamines from the medulla in order to activate the sympathetic 
nervous system (SNS). This “fight or flight” response allows for the body to act upon 
the perceived threat at hand. In addition to these hormones being secreted 
endogenously, these substances are administered as exogenous pharmacologic 
medications commonly meant to support a falling blood pressure along with 
treatment for a multitude of other conditions. It is known that elevated levels of 
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cortisol and epinephrine contribute to impairment of the immune system, placing the 
patient at a heightened risk for infection (25).  
Opioids 
Critical illness is often accompanied by pain, either as a result of an injury or a 
disease process. Opioid analgesics are used frequently to treat this pain, but also may 
be used for sedative properties. Regardless of the intended use, opioids possess  
powerful immunosuppressive properties. Another well known side effect of opioids is 
slowing of GI motility. Delayed peristalsis incurred with opioid administration can 
increase the risk of translocation of bacteria out of the GI system where they can 
become pathogenic to the host (26). Additionally, treatment with opioids is known to 
place the patient at an increased risk for CDI due to the associated alterations in the 
GI microbiome and immune function (27,28).  
Probiotics: What are they, how they vary, and how they can restore the 
microbiome 
Probiotics can be simply defined as microbial cells that confer beneficial effects on 
the health of a human host and are naturally found in many foods (5). Some of the 
most common probiotic-rich foods include yogurt, cultured vegetables (sauerkraut 
and kimchi), kefir, and kombucha (see Table 1). However, recent interest has 
emerged in consuming probiotic supplements in pill, powder, or capsule form to 
achieve these same benefits. There has been an incredible increase in the number of 
manufacturers producing and marketing various species and strains of these beneficial 
microbes to assist in not only digestive health, but also for immune support and as an 
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adjunct to a healthy lifestyle. Under the Dietary Supplement Health and Education 
Act (DSHEA), a manufacturer of a supplement cannot claim its substance has the 
capacity to diagnose or cure any particular disease. However, making broad claims 
such as “improves overall health and well-being” has proven to be quite a draw for 
the current health-conscious society. Since probiotics mostly are used as a dietary 
supplement, they do not face stringent regulation by the Food and Drug 
Administration (FDA).  
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The fad 
The draw of being “healthy” and “boosting immunity” is captivating the interest of both 
the researcher and the consumer, and manufacturers and marketing companies are 
capitalizing on this. In fact, the probiotic movement has spread such that you can find 
probiotics in foods like granola bars, bottled water and juices, and even chocolates.  
With the growing interest and application of probiotics for specific conditions and overall 
health claims, these “healthy microbes” will continue to find their way from the shelves 
to our bellies. Some of the more common and popular brands include: Align®, 
Culturelle®, Florastor®, Ultimate Flora Extra Care®, Synbiotic 2000 Forte®, Floratrex®, and 
Raw Probiotics Women® (see Table 2).  
The facts 
Both foods and supplements have been developed and marketed with the intention to 
enhance wellness in healthy individuals as well as for the dietary management of various 
diseases. In the U.S., probiotics are regulated as dietary supplements unless a particular 
product is marketed for having a role in treating or preventing a particular disease. Rather 
than focusing on quality, safety, and efficacy, regulational oversight focuses on the 
legitimacy of any claims made by the manufacturer (29). Depending on the intended use, 
regulatory oversight and requirements for probiotics differ greatly (30). “Nutritional 
supplements” are considered a food and therefore regulated by the FDA’s Center for 
Food Safety and Applied Nutrition. However, if the intent is to use a substance for a 
cure, mitigation, treatment, or prevention of a disease, then it can be classified as a drug 
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by the FDA (31). Manufacturers explicitly state on labeling that the product “is not 
intended to diagnose, treat, or mitigate disease” in order to be in compliance with the 
FDA. However, clinicians are often using probiotics for those purposes. 
Manufacturing practices, conditions, and ingredients play a major role in the 
determination of product characteristics and properties. Again, current law may allow for 
a variety of formulations to be sold under the same brand which may account for a 
product different from the original. Such regulatory deficits may have dire consequences 
on consumers as well as for prescribers using these preparations as part of clinical 
guideline-recommended management of various problems or diseases. A prescriber can 
be liable for prescribing a formulation of a product not properly tested for safety or 
efficacy. For these reasons, current regulations are not sufficient to protect consumers or 
providers. Further regulatory oversight is warranted (29).  
As aforementioned, when used for nutritive value, probiotics are considered a 
supplement and therefore not subject to the scrutiny of the FDA. In light of the recent 
research examining their use for preventing and treating certain diseases, the FDA 
responded by defining probiotics as a biotherapeutic product and mandating that any 
clinical research done with probiotics requires an Investigational New Drug (IND) 
application when conducting research that is beyond using them as nutritive supplements. 
This holds probiotics to increased scrutiny and places barriers to advancing research in 
this area. Manufacturers must provide required information to the FDA. Exclusion 
criteria set forth by the FDA includes pregnancy, immunosuppression, structural heart 
disease, or a leaky bowel wall.   
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The fiction 
It is important to dispel a common myth regarding probiotics—all probiotics are not the 
same. In fact, a particular supplement itself may vary bottle to bottle. Several 
commercially available products vary between the actual microbial composition (at either 
the species or genus level) and what is labeled on the container (32). Further, the colony 
count of species may be far different from labeling, due, in part, to mishandling the 
product once it leaves the manufacturing facility. Accounting for this variability is the 
lack of regulation and oversight over the probiotic market. Probiotics are live organisms 
and are extremely sensitive to their environment. The manufacturing process and 
handling of the products themselves are not always the same. In addition, many of the 
properties of probiotics are not only species but strain specific (33). This means that 
safety and efficacy of findings should not be generalized to similar products (29). 
Use of probiotics/evidence-based use of probiotics 
VAP 
VAP, a type of hospital acquired pneumonia, is the second most common nosocomial 
infection in the U.S. and the most frequent HAI in intensive care units (34). In fact, it is 
estimated that as many as 30% of mechanically ventilated patients develop VAP (35). 
Similar to other HAIs, VAP is associated with poor clinical outcomes and high financial 
burden, with estimates close to an additional $40,000 of hospital costs per patient (34). 
VAP can be diagnosed in any critical care patient who has been mechanically ventilated 
for at least 48 hours and demonstrates clinical symptoms of pneumonia along with 
displaying relevant radiographic criteria (36). VAP has long been an outcome indicator 
of quality of care and infection prevention strategies among critical care units. More 
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recently, the concept of infectionrelated ventilator complications (IVAC) and ventilator 
associated complications (VAC) have been proposed by the CDC to expand upon VAP 
as more objective measures of quality of care, since the diagnostic criteria of VAP may 
be interpreted differently by clinicians (37). A further discussion on the nosology and 
etiology of VAP, IVAC, and VAC are beyond the scope of this discussion.  
Bundles of care specific to ventilated patients have been proposed and implemented 
across the world as effective healthcare-associated pneumonia prevention strategies (37). 
It is predicted that incidence of VAP can be decreased by 50–60% if evidence-based care 
bundles are instituted and properly followed by all medical staff a part of the care of 
mechanically ventilated patients (38). Essential components of these bundles, as 
explicated by the Institute for Healthcare Improvement, include: daily interruption of 
sedation with wakening and weaning trials, elevation of the head of the bed to at least 45 
degrees at all times, deep vein thrombosis prevention with pharmaceuticals and 
sequential compression devices, pharmacologic prevention of intestinal bleeding and 
gastric ulcers, and frequent oral care, perhaps with chlorhexidine (39). In light of current 
research regarding the efficacy of probiotics on decreasing incidence of VAP, it may be 
worth considering probiotic supplements as part of ventilator care bundles.  
With an understanding of how probiotics positively influence host gut-barrier health, it 
should come as no surprise that there is a growing body of evidence demonstrating the 
positive effects probiotics have on incidence of hospital-acquired infections, including 
VAP. Probiotic therapy may prevent and treat VAP by restoring non-pathogenic bacteria 
that compete with pathogens for binding sites and growth substrates, modulating host 
immune response, and augmenting gut mucosal barrier function. One particular species 
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of probiotics substantiated by the literature regarding safety and efficacy is Lactobacillus 
rhamnosus GG (LGG). In a study by Morrow et al., administration of LGG was 
associated with a significant reduction in the incidence of VAP with microbiological 
confirmation on invasive lower respiratory tract samples (40). However, when examining 
the total body of evidence pertaining to the therapeutic use and safety of probiotics, there 
remains inconsistency of results (34). Further research is warranted to better understand 
what exact species and dosing as well as what time is ideal for introduction to the host to 
prevent and combat VAP.  
CDI  
CD and CDI is a frequent cause of hospital acquired infection and significantly increases 
a patient’s morbidity and mortality. In 2008, 66 out of 100,000 patients were infected 
with CD; a rate which doubled from that just eight years prior. Risk factors for CDI are 
advanced age (age greater than age 65), prolonged hospital stay, female sex, 
immunocompromised, and recent antibiotic administration, among others (41). In fact, 
just one dose of an antibiotic can severely alter a host’s microbiome to the point where 
opportunistic pathogens like CD can proliferate and cause illness for an extended period 
of time (42). Current recommended treatment approaches include metronidazole for mild 
to moderate cases of CDI and vancomycin for severe cases. These antibiotics often result 
in recurrent CDI, however, due to their broad-spectrum coverage that destroys not only 
CD but also host microbiota. Recent studies aspire to find a new, narrow-spectrum 
antibiotic, such as thuricin CD, with specific anti-CD coverage to reduce the collateral 
destruction on host microbiota (42).  
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In addition to the effect a more narrow-spectrum antibiotic may have on mitigating the 
destruction of host flora during treatment of CD, concurrent supplement with probiotics 
may prove beneficial. A recent meta-analysis by Johnson et al. found moderate-quality 
evidence suggesting that supplemental therapy with probiotics resulted in a significant 
reduction in incidence of CD-associated diarrhea without any association of increased 
adverse events. In fact, when examining 20 trials that included over 3,800 patients, 
Johnson et al. saw a 66% reduction of CDassociated diarrhea when patients were 
supplemented with species of Bifidobacterium, Lactobacillus, Saccharomyces and/or 
Streptococcus in patients receiving antibiotics. Trials that used multiple species showed 
greater effects than those using a single species. Their findings offer reason to encourage 
the use of probiotics in patients receiving antibiotics who are at risk for CDI and CD-
associated diarrhea (43).  
Furthermore, Lau and Chamberlain also conducted a meta-analysis to ascertain the 
efficacy of probiotics on reducing the incidence of CDI. They examined 26 randomized 
controlled trials that included a total of 7,957 patients. Lau and Chamberlain found that 
probiotics had an effect of 60.5% reduction on the incidence of CD-associated diarrhea. 
Specifically, treatment with Lactobacillus, Saccharomyces, or a mixture of probiotic 
species reduced CD-associated diarrhea by 63.7%, 58.5%, and 58.2%, respectively. 
Again, the variation and heterogeneity of trials accounts for a major limitation of 
findings; however, probiotics should still be considered a valuable adjunct in the 
therapeutic regimen of patients receiving antibiotics unless otherwise contraindicated 
(44). Finally, Goldenberg and colleagues conducted a Cochrane review that found 
probiotics decreased the risk of CD-associated diarrhea by 60% in patients who were not 
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immunocompromised or in a severely debilitated state. Based on data from this meta-
analysis of 31 randomized controlled trials including over 8,670 patients, researchers 
concluded that moderate certainty evidence suggests that concurrent probiotic use along 
with antibiotics is a safe and effective strategy for preventing CD-associated diarrhea 
(45). 
CAUTI 
A urinary tract infection (UTI) occurs when the urethra is colonized with uropathogens 
or fecal flora. These organisms include E. coli (50%), Proteus (15%), Enterobacter 
(15%), and Klebsiella (15%), among others with less significant rates. Uropathogens can 
further spread down the urethra to the bladder and possibly the kidneys via the ureters. 
Such UTIs account for many cases of cystitis and pyelonephritis (46). What’s more, 
significant comorbidities resulting from UTIs include urethral stricture, abscess or fistula 
formation, bacteremia, and sepsis. An astonishing 25% of all sepsis cases emanate from 
UTIs (47).  
Among all cases of healthcare-associated UTI, approximately 75% are associated with a 
urinary catheter. It is estimated that between 15–25% of hospitalized patients receive 
urinary catheters at some point in their stay (48). Indwelling urinary catheters are often 
necessary for critically ill patients in order to monitor intake and output and to alleviate 
urinary outflow obstruction, for example, but they are a major source of preventable 
infection. Improper handling and poor hygiene can result in contamination of the catheter 
which allows for pathogenic organisms to invade the urinary tract. Additionally, urinary 
catheter drainage bags serve as potent bacterial reservoirs. 
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The risk of contracting a CAUTI increases with prolonged use of the catheter. Therefore, 
urinary catheters should be removed as soon as clinically warranted. Unfortunately, the 
research regarding the efficacy of probiotics on the prevention of CAUTI is limited. At 
this time, there is not enough evidence to assert that probiotics may be an effective 
choice for CAUTI prophylaxis. However, in light of recent research regarding the 
efficacy of probiotics for preventing UTIs in general, studies with the intent to ascertain 
the efficacy of probiotics for prevention of CAUTI specifically is warranted.  
Recently, researchers sought to review the safety and efficacy of probiotics in the 
prevention of UTI, given that probiotics have other potential uses as prophylactic 
therapies. Schwenger et al. reviewed the effect probiotics had on morbidity and mortality 
compared to placebo or no therapy in patients susceptible to UTI. They included nine 
studies that involved over 730 patients. The focus of these studies was to quantify 
differences in incidence of recurrent UTI. Researchers found that no significant benefit 
with probiotics therapy compared with placebo or no treatment; however, a benefit 
cannot be ruled out for several crucial reasons. These include a data set that was too 
limited and use of small studies with poor methodological reporting (47).  
SSI  
Roughly 1.5 million of the 80 million surgeries performed in the U.S. each year is 
complicated by a SSI. Post-SSIs are the most common of all HAIs, comprising 
approximately 30% of the total number of these infections. SSIs can add 7 to 11 
additional postoperative days to a patient’s stay and increase mortality by up to 11 times. 
Among perioperative patients, 77% of deaths are directly attributed to SSIs (49). Septic 
morbidity and mortality associated with surgical and medical treatments is high and 
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rising all over the world, with estimates around 200,000 annual deaths in the U.S. 
attributed to sepsis (50). Researchers and clinicians are continuously exploring ways to 
reduce the incidence of infective complications and other surgical adverse events in 
perioperative patients. Evidence suggests that surgical trauma disrupts the gut 
microbiome and allows for translocation of normal gut flora. The gut itself is closely 
linked to the initiation of systemic inflammatory processes that are, in part, responsible 
for the development of sepsis following surgery.  
Recently, perioperative nutrition modulation of gut flora is increasingly being used as an 
outcome improvement strategy. Probiotic, prebiotic, and synbiotic therapies are being 
substantiated by the literature as effective means to mitigate the disruptive effect surgical 
trauma has on gut function. For reference, a prebiotic is a food substance that positively 
influences growth and survival of host microbiota and a synbiotic is a product that 
contains both prebiotics and probiotics (51).  
A meta-analysis performed by Kinross et al. explored the effect probiotic and synbiotic 
therapy had on postoperative sepsis rates (52). Over 960 elective surgery patients from 
13 randomized controlled trials were sampled with the primary outcome measure being 
postoperative sepsis rate. Of the 962 patients, 304 received synbiotics and 182 received 
probiotics either postoperatively or pre- and postoperatively. Probiotics used were of the 
Enterococcus, Lactobacillus, Lactococcus, Leuconostoc, and Bifidobacterium species. 
Researchers found that the rate of postoperative sepsis was reduced in both the probiotic 
and synbiotic groups compared to the control group.  
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Prevention above all else 
Although decreasing costs associated with the development of infections is important, the 
main reason to prevent HAIs is to improve outcomes and save lives. Deaths attributed to 
critical illness/sepsis have been increasing more quickly than any other cause of mortality 
in this population, making infection prevention strategies even more critical (34).  
Safety and risks associated with probiotics 
The rapidly expanding consumer probiotic market is reaching into the acute care setting. 
While research with probiotics for the prevention and treatment of certain ailments in 
otherwise healthy people is not new, the theoretical benefit of restoring a healthy 
microbiome for a person that is acutely ill and at increased risk for infection is being 
explored with great interest. Their use in the acute care setting has been quite promising, 
but the use of probiotics in the critical care setting has caused significant controversy. 
Research with probiotics demonstrates their efficacy in preventing and treating various 
conditions, particularly those involving the GI tract, but can they be harmful? There are 
certain patient populations in whom risks versus benefits must be carefully considered. 
Although the overwhelming evidence supports that probiotics are safe, there are case 
reports of risks associated with probiotic use as well as some theoretical risks that have 
been posed in certain patient populations.  
The most widely cited safety concern surrounding probiotics is the possibility for 
bacteremia and fungemia associated with their use in certain high risk groups. Adverse 
effects of probiotics are not widely reported in studies, yet case reports of infection 
possibly related to concomitant probiotic use have been reported. Most of these 
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infections occurred in “vulnerable” groups (53). Even though their overall safety has 
been confirmed in literature reviews, caution still needs to be taken in certain situations. 
A systematic review published in 2014 concluded that probiotics are safe, yet caution 
should be taken when using probiotics in populations such as those that are critically ill 
in the recent postoperative period and immunocompromised (54). Case reports of 
infection also have been reported in patients with short bowel syndrome, central venous 
catheters, and patients with cardiac valve disease or mechanical heart valves (53,55,56). 
The risk of infection may also be related to improper handling of the probiotics 
themselves.  
Systemic infections have been cited; cases of Lactobacillus bacteremia and fungemia 
associated with the administration of Lactobacillus probiotics and Saccharomyces 
species in patients who also had central lines have been reported (30,55,57,58). These 
preparation (usually capsules or sachets) often need opened for administration through a 
feeding tube which is a practice that can potentially spread the microbes into the air and 
cause them to contaminate the hands of healthcare workers (59). Improper hand washing, 
then, can cause a translocation to a central line catheter where the microbes have direct 
entry into systemic circulation. Although the manufacturers of some of these products list 
on the label that they are not to be administered to patients with central lines, this 
practice still does occur. Precautions must be taken to avoid the accidental contamination 
of the central line of the patient receiving the probiotic or those with central venous 
catheters in the close proximity to the patient receiving the probiotic (60).  
Other safety concerns have been cited by researchers and healthcare practitioners, 
including the possibility of gene transfer from the microbe itself, toxins being produced, 
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and effects on a person’s immunological system. It is theoretically possible for certain 
microbes to transfer gene resistance to the host. Certain Lactic acid bacteria have genes 
resistant to common antibiotics such as macrolides and chloramphenicol (55). Although 
this does remain a possibility, no literature to date supports this theoretical risk to 
humans.  
Commercially available probiotics may contain a single or multiple strain of a particular 
microbial species. This could either be multiple strains of the same species, or strains 
from more than one genus (29). Different products contain varying amounts of bacteria 
or fungi, so safety related to the quantity of living microbes being ingested is a concern. 
Additionally, with each species or strain added to a preparation, concern regarding the 
adverse effect profile, or safety, of each is necessary. 
It is known that probiotics affect both our innate and adaptive immune systems, so 
concern has been raised over the possibility of over-stimulating immune function in 
certain individuals. Theoretically, this could lead to an “awakening” of an autoimmune 
disease in the host. However, this too has not been evident in the literature thus far (8). 
There is a scarcity of studies that specifically examine the safety profile of probiotics 
when administered to the critically ill. Considering the long history of safe use of 
probiotics coupled with the actual and potential risks associated with improper 
administration or certain vulnerable groups, it is best for clinicians and researchers to 
take precautions. This includes conducting a careful risk/benefit assessment for certain 
patient groups. When using probiotics, active surveillance for cases of infection 
associated with probiotic use along with laboratory confirmation of causative organisms 
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and vigilant reporting of same is important for establishing a safety profile for their use 
in the critically ill population.  
Conclusions 
Despite lack of clear, scientific evidence on efficacy, the appeal for consumption and sale 
of probiotic supplements and probiotic foods continues to grow. Beyond the role they 
play in promoting GI health, probiotics have been studied and shown to facilitate 
restoration of the microbiome. Despite lack of homogeneity and the number of high 
quality studies, published research shows much promise for the use of probiotics to 
restore altered microbiota and therefore confer substantial benefits to the critically ill; 
namely the prevention and, in some cases, amelioration of infection. Therefore, an ethical 
conundrum exists for healthcare providers and a risk-benefit ratio must be explored. 
Does the administration of probiotics to critically ill patients, despite lack of clear clinical 
guidelines, offer significant benefit?  
Certainly, a precautionary approach is warranted (61). It is important for clinicians to 
distinguish between the reality of what is presented in the marketing of probiotics, what 
is known from research, and purely theoretical benefits and potential harms associated 
with their use. In essence, current evidence supports a role for probiotics in the critical 
care setting. However, results, in their current form, must be interpreted cautiously in 
order to ascertain what this legitimate role may be and which species and strains will 
provide the most benefit. 
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Chapter 4 
Part 3 
 
The final manuscript for the research project is included.  A discussion of the data 
analysis and significance of the findings is included. 
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Abstract 
Background: Infection is a leading cause of death in patients who survive trauma. Traumatic 
injury/critical illness cause dysbiosis; disruption in intestinal flora that normally affords immune 
protection. Probiotic usage in trauma patients for infection prevention is being studied. 
Objectives: To investigate the influence of probiotic supplementation on infection rate in trauma 
patients. Variables: probiotic usage, mechanical ventilator days, hospital length of stay (LOS), 
mortality, and antibiotic usage. 
Methods: Cross-sectional study in a Level 1 trauma center. Trauma admission medical records 
from January 2017 through June 2018 were reviewed for infection events and probiotic usage. 
Infection rates for patients receiving probiotics was compared with those who did not. 
Results: After exclusion for infection-probiotic timing and stratification by patient acuity, 1,055 
cases were analyzed. Adjusting for patient acuity, the high patient acuity group was too 
underpowered for interpretation. For both groups, results were impacted by a low probiotic usage 
rate; 85% of the patients eligible to receive probiotics did not. In the low patient acuity group, the 
infection rate for those receiving probiotics was 8.2% versus 1.8% in the group not receiving 
probiotics. The sample sizes varied (n=147 and n=856, respectively) which warrants caution with 
interpretation of results. 
Conclusion: No benefit for the prevention of infection was found in this study.  Several study 
limitations likely influenced results; low infection rates and low probiotics usage rates. 
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Background 
Results of previous research are mixed and have shown both benefits and 
(potential) risks to probiotic use in trauma patients.  For patients who survive the initial 
“first hits” of trauma, namely severe organ injury, hypoxia, and 
hypovolemia/hemorrhage, sepsis is a leading cause of death (Goris & Draaisma, 1982; 
Lenz et al., 2007; Lord et al., 2014).  Trauma patients who experience a healthcare-
associated infection (HAI) not only have increased mortality rates and longer lengths of 
stay, but also have increased costs associated with their care (Glance et al., 2011).  The 
yearly costs associated with treating HAIs exceeds 9.8 billion dollars (Zimlichman et al., 
2013).  Patients who suffer a traumatic injury are at increased risk for developing HAIs, 
particularly with multidrug resistant organisms (Fawzy et al., 2017), due to a host of 
factors including the nature of the traumatic injury itself.  Traumatic injury and the stress 
of a critical illness cause an intestinal dysbiosis; an overgrowth of pathogenic bacteria 
that replaces or overwhelms the gastrointestinal (GI) microbiome of commensal 
organisms (Manzanares, Langlois, & Wischmeyer, 2017; Lee E Morrow & Wischmeyer, 
2017; Young, 2017).   
The microbiome and resident microbiota, the collection of all genomes of all 
microbes in an ecosystem and the microbes that inhabit that ecosystem (Lynch, 2016), 
play a crucial role in homeostasis and immune response, and normally serve to protect us 
from infection and disease that is caused from potentially pathogenic microbes (Vieira, 
Teixeira, & Martins, 2013; Young, 2017).  There is increased personal interest in the use 
of probiotics to aid in overall digestive health, but there is growing professional interest 
as well for a variety of uses.  Research into restoring the human microbiome in critically 
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ill patients for the treatment and prevention of certain diseases has been increasing over 
the last decade.  Considerable research has been conducted on the use of probiotics for 
prevention of ventilator-associated pneumonia (Bo et al., 2014; Cook et al., 2016; Zeng et 
al., 2016), Clostridium difficile (C. diff) infection (Barker et al., 2017; Evans & Johnson, 
2015), antibiotic-associated diarrhea (Mantegazza et al., 2017; Vandenplas et al., 2009), 
helicobacter pylori eradication (Zhang, Qian, Qin, He, & Zhou, 2015) as well as many 
other disease processes.  However, controversy still exists on their role and application to 
hospitalized patients; especially those that are critically ill or suffer a traumatic injury 
(Fawzy et al., 2017; L. E. Morrow, Gogineni, & Malesker, 2012).  Beyond the question 
of efficacy, those in the medical and science community cite concerns over the safety of 
using a substance for patients that does not have strict Federal Drug Agency (FDA) 
regulatory oversight (Doron & Snydman, 2015; L. E. Morrow et al., 2012; Venugopalan 
et al., 2010; Vitko et al., 2017). 
 
Background of Probiotics 
Probiotics are living organisms that are found in many forms.  They are naturally 
occurring in fermented foods, mostly dairy products, but are also commercially available 
and sold over-the-counter in pill, powder, and capsule form.  They can be found added to 
a wide variety of foods and drinks that can be purchased in nearly all supermarkets.  
Probiotics, when used for the intent of supplementing the diet are considered “dietary 
supplements” as defined by the Dietary Supplement Health and Education Act.  In this 
use, they are not regulated nor face stringent rules and regulations by the FDA.  When a 
“supplement” is prescribed by a physician for the intent of dietary management of a 
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medical condition, it can be considered a “medical food”.  The contents of a medical food 
must have scientific research to back any claims such as being “for digestive health”, but 
the FDA does not require proof of these studies.  Further, information about any possible 
adverse effects is not required on the labeling.   
The only oversight the FDA has with a dietary supplement or a medical food is 
that they are manufactured using Good Manufacturing Practice (de Simone, 2018) and 
the contents are reasonably expected to be safe for human consumption (Venugopalan et 
al., 2010).  Manufacturers of supplements, however, do not necessarily comply with 
assuring proper sanitation and quality control within their manufacturing facilities.  In 
fact, in fiscal year 2017 the FDA found that nearly one-half of the 656 facilities it 
inspected had violations in proper sanitation practices (Cohen, 2018). 
Another area of concern surrounding the non-regulation by the FDA involves 
oversight once the supplement leaves the manufacturer.  These substances are not 
subjected to any quality control once they leave the manufacturing plant (de Simone, 
2018; Kolacek et al., 2017).  Most probiotics that are marketed to consumers are prepared 
in pill, capsule, or powder form.  Since probiotics are living organisms, viability from 
manufacturer to consumer can be a challenge especially when they are not “naturally” 
occurring such as in normally refrigerated foods.  In pill or capsule form, they usually are 
lyophilized, affording them stability at room temperature and therefore a longer shelf life.  
However, these living organisms are easily killed by poor handling practices such as 
humidity and heat extremes (Kolacek et al., 2017).  Therefore, any probiotic preparation 
must be viewed as “buyer beware” since the label may differ from the actual number of 
live colonies within the package(de Simone, 2018; Kolacek et al., 2017; Sanders et al., 
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2010).  Another issue of quality control is the labeling of the packaging.  Labeling and 
actual content of the bottle can vary with regard to the species or strain of the probiotic  
(Huys et al., 2006; Long, 2018; Theunissen et al., 2005).  This must also be taken into 
consideration when using probiotics in the clinical setting, especially when any type of 
research is being conducted regarding a certain strain or dosage/potency for efficacy. 
The tide may be changing, however, with regards to the regulation of the growing 
probiotic market.  In January 2017, scientifically-based best practice guidelines were 
released by the Council for Responsible Nutrition and the International Probiotics 
Association.  These guidelines call for self-regulatory practices to include standards for 
labeling, storage, and stability testing of foods and supplements that contain 
probiotics(Wong, October, 2017).  Perhaps as more stringent regulatory guidelines are 
put into place, assuming manufacturing companies follow these guidelines, consumers 
may begin to place more confidence and trust into these substances. 
Inconsistency in the Research 
The published research on the use of probiotics in the acute care setting has 
mostly shown favorable findings with respect to decreased infections and improved 
outcomes.  However, the development of clinical practice guidelines on their use has 
been difficult since, as many systematic reviews and meta-analyses have shown, there is 
considerable heterogeneity with respect to the strain, dosage, and timing of probiotic 
administration(Manzanares, Lemieux, Langlois, & Wischmeyer, 2016; L. V. McFarland, 
2015; Petrof et al., 2012).  Further, many trials are of poor quality, single-center, or with 
an insufficient number of patients (Bo et al., 2014; Manzanares et al., 2016; Petrof et al., 
2012; Siempos, Ntaidou, & Falagas, 2010; Zorzela, Ardestani, McFarland, & Vohra, 
  
128 
 
2017).  And, as mentioned before, unless the probiotic is being tested within the acute 
care setting for species content and viability, efficacy based on these parameters may 
vary.  Of note, however, there is research being conducted on “dead” or “modified” 
(inactivated by heat or sonication) probiotics examining whether killed or attenuated 
probiotic organisms may still confer some immunity or anti-inflammatory benefits 
(Theunissen et al., 2005; Zorzela et al., 2017),(Sarkar, 2018).  Possible differences in 
safety risks associated with living versus non-living probiotic organisms is also being 
investigated.  
Concerns over the safety of probiotics being administered to hospitalized patients, 
including those that are critically ill, was addressed by the Agency for Healthcare 
Research and Quality.  They commissioned a comprehensive review based on 622 
published studies and concluded that although the available evidence does not indicate an 
increased risk to safety with the administration of probiotics, they cannot confidently 
confirm their safety due to a lack of adverse events related to the use of probiotics being 
documented in the literature (S. Hempel et al., 2011).  Other researchers examining the 
safety of probiotics in published studies also caution interpretation since many of the 
studies they reviewed were too small to detect events and others did not specifically 
report safety or adverse event data (Zorzela et al., 2017).  
There have been case reports in the literature of fungemia or bacteremia 
associated with the administration of Saccharomyes boulardii (a yeast) and some strains 
of Lactobacillus, but these reports are rather rare considering the millions of doses of 
probiotics that have been administered to hospitalized patients (Doron & Snydman, 
2015).  So, although it appears that administering probiotics to even higher risk 
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populations is likely safe, there still exists some doubt and skepticism among healthcare 
providers.  A conundrum exists in that replenishing depleted microbiota may offer 
immune protection to those at most risk, yet the supplement meant to protect may 
actually cause an infection.   
Current research on not only the efficacy but the safety of living versus modified 
probiotics is relatively new but on-going.  The principal theoretical risk associated with 
probiotic administration is the possibility that living microbials, although part of our 
normal commensal flora, can actually cause an infection if they somehow colonize 
outside of the GI tract (Boumis, Capone, Galati, Venditti, & Petrosillo, 2018; Doron & 
Snydman, 2015; S. Hempel et al., 2011; Perry & Doron, 2018).  Additionally, ill-effects 
from potential contaminants to the probiotic substance from the manufacturing process or 
handling of the substance is possible.  Although a review in 2010 found that heat-killed 
probiotics had fewer adverse effects when compared to living (Sanders et al., 2010), a 
more recent review found that the rate and type of adverse events caused by living and 
modified probiotics to be largely similar(Zorzela et al., 2017).  Clearly additional 
research is warranted.   
 
Probiotics in Patients with Alterations in Health 
Probiotics have been used for centuries by healthy people.  The recent interest in 
using them in people with altered health status warrants some caution.  Vigilance should 
be used when considering the administration of probiotics to certain populations, such as 
those who are immunocompromised, those with mechanical heart valves, or those with 
the potential of translocation of the probiotic across the bowel wall (Didari et al., 2014; 
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Doron & Snydman, 2015).  Other reports of infection, including systemic infection, likely 
caused by probiotics may have occurred due to contamination of the air and hands of 
health care workers.  Probiotics are living microbials that are beneficial to humans when 
they inhabit the GI tract, but can become pathogenic outside of the GI system.  This can 
happen when probiotics in powder form or capsules are opened for administration 
through an enteral tube and then unknowingly transmitted to a patient through a route 
other than for which they were intended.  Case reports of systemic fungal infections 
related to Saccharomyces boulardii precipitated the manufacturer to label Florastor® 
with the warning “not (to) use Florastor® probiotics in the acute-care setting” and “not 
(to) use for any individual with a central line or port or in the surroundings of any patient 
with a central line or port” . 
Despite the lack of clear clinical practice guidelines, inconsistencies in the 
literature regarding strains and efficacy, and caution statements regarding the potential 
for causing infection, current evidence strongly suggests that probiotics are largely safe 
and may be efficacious for certain outcomes.  Prevention of infection and, ultimately, 
decreasing the need for antibiotics, is imperative for the vulnerable trauma population.   
The goal in medical research is to use available knowledge to formulate 
hypotheses that can be used to potentially prevent, treat, or ameliorate illness and disease.  
However, as with any new ideas, benefits must outweigh risks in the absence of true 
clinical certainness; especially in the case where not having enough evidence does not 
justify inaction.  The Expected Utility Theory (EUT) is a theory of how people should 
make decisions and can be useful for medical decision-making when there is a lack of 
clear evidence of efficacy and risk.  Current literature supports that administering 
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probiotics to acutely ill patients is ethically justified since the probability of the desired 
outcome (decrease in infection rates) would likely be realized for the greatest number of 
people.  In this study, we examined the effects of the administration of probiotics on 
incidence of infection in hospitalized trauma patients meeting inclusion criteria. 
Objectives 
Two of the most commonly studied and readily available probiotics are 
Lactobacillus Rhamnosus GG (LGG, Culturelle®) and the yeast Saccharomyces 
Boulardii (S. boulardii, Florastor®).  These two probiotic types are widely available and 
have rather stable shelf lives.  The objectives of this study were to examine through 
retrospective data collection whether there is a difference in the incidence of infection 
rates in trauma patients who have and have not received either LGG and/or S. boulardii 
probiotic supplements during hospitalization.  Additionally, since the administration of 
probiotics to this population was new and somewhat inconsistent, we examined 
probiotics usage rates.  Secondary outcomes also included: hospital length of stay, 
ventilator days (as applicable), mortality and antibiotic requirements. 
Materials and Methods 
Study Setting 
 A Level I trauma center and teaching hospital in western Pennsylvania that 
receives an average of 1200-1400 trauma patients per year was the setting for this study.  
The impetus for this study began in 2015 when some trauma physicians began 
prescribing probiotic supplements for their patients based on findings of recent studies 
that suggested improved outcomes such as reduction of C. diff and ventilator-associated 
pneumonia (VAP).  At this time, there was a push to implement a probiotics 
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administration protocol whereby all adult trauma admissions that did not meet exclusion 
criteria would be administered two strains of probiotic supplementation; LGG and S. 
boulardii.  The attending trauma surgeons agreed that probiotics should be ordered on 
admission, however since it was not possible at the time for this “probiotics protocol” to 
be included on the electronic admission order set, compliance with ordering was low.  
Toward the end of the study period, the use of probiotics did increase (10% ordering 
compliance in 2017 and 26% ordering compliance in 2018) and finally, near the 
conclusion of data collection, a formal probiotics administration protocol was approved 
and included in the electronic trauma admission order set (See Table 1). 
 
Table 1: Patient Population Inclusion/Exclusion 
All adult trauma admissions, 18 years of age and older, admitted between January 1, 
2017 and June 30, 2018 adhering to the following inclusion/exclusion criteria: 
 
Inclusion Criteria 
(ANY of the following): 
 
Exclusion Criteria  
(do NOT start probiotics if ANY criteria 
are met): 
 
o Antibiotic administration 
o Mechanical ventilation 
o Anticipated LOS > 48 hrs 
 
o Age <18 
o Current/recent use 
Immunosuppressive agents:  
o TNF blockers 
o MABs  
o Chemotherapy 
o Chronic corticosteroids 
o Anti-rheumatic drugs 
o Anti-rejection drugs 
o Cardiac valve surgery 
o HIV/AIDS 
o Active malignancy  
o Pregnancy 
Table 1:  All adult trauma patients meeting above criteria were to be prescribed LGG 1 capsule daily and S. boulardii 250mg twice 
daily 
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Measurement of Outcomes 
 The primary outcome was the development of a HAI.  Secondary outcomes were 
probiotic usage (compliance with ordering of probiotic supplements according to the 
protocol), hospital length of stay (LOS), mechanical ventilation days (MV, as applicable), 
mortality, and antibiotic requirements.   
 
Methods 
 Upon receiving IRB approval from Duquesne University and Conemaugh 
Memorial Medical Center, medical records for trauma admissions between the specified 
dates (July 2014 through December 2017) were reviewed for incidences of infection.  
Additionally, medication administration records were reviewed for probiotic and 
antibiotic usage.  Timing of initiation and duration of probiotic and/or antibiotic usage 
was extracted and then compared to those patients that developed an infection.  At the 
time of IRB approval, the study hospital had recently transitioned electronic health record 
systems.  Data prior to January 2017 was not suitable for this project due to the lack of 
detail necessary for analysis and was, therefore, not included.  Statistical analysis was 
performed on data obtained from January 2017 through June 2018. 
 
Data Collection and Statistical Analysis Plan 
 Data was extracted from multiple databases: trauma, infection control, and EPIC 
medical record system.  The study population was determined from the hospital trauma 
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database filtered by the inclusion/exclusion criteria.  The Infection Prevention 
Department provided an accounting of all healthcare-associated infections as identified 
per the current Centers for Disease Control (CDC-NHSN) regulatory and reporting 
guidelines; additional infection events were obtained from the trauma database.  These 
infections were recorded in accordance with the quality control and constant outcome 
improvement processes designed and implemented by the Department of Trauma.  
Finally, the hospital EPIC report team created a detailed data extraction tailored for this 
project.  The EPIC data extraction contained all needed details regarding medication 
taken and timing thereof.  The information from these multiple extractions were 
coalesced and correlated into a single study data set for analysis.  The EPIC data was 
aggregated by unique medical record number (MRN)-admit date pair; after which, the 
type, dose count taken, timing, and days taken for antibiotics and probiotics were 
calculated.  MRN-admit pair was then used to combine all needed information from the 
three data extractions per each unique patient encounter.  The final data set was imported 
into SPSS version 25 for analysis.  An overall alpha equal to 0.05 was set.  
 
Results 
The unsuitability of data prior to January 2017, as described earlier, necessitated 
collection of additional data. Following IRB approval (amendment) allowing an increase 
of the study time period, the data collection process detailed previously was repeated for 
records from January 2017 through June 2018, yielding a data set of 1,059 records of 
admitted trauma patients.  Infection events were obtained from two separate data bases; 
infection control department and the trauma database.  We identified 4 infection events 
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from the infection control database that occurred either prior to the initiation of 
probiotics, or probiotics were started on the same day.  These were excluded from 
analysis since there would be no influence on probiotics to infection in those cases.  
When examining the trauma database for infection events, we were unable to determine 
onset of date of infection related to probiotics administration so we could not determine 
how many, if any, of these infections occurred independent from probiotic usage.  This is 
a major limitation to analysis and findings.
 
Figure 1:  Flow diagram of sample data set derivation  
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Attempting to accommodate the potential confounding influence of patient acuity, 
the data was stratified by ISS, specifically, cases with ISS > 25 (n=52) were stratified into 
a high patient acuity group, while the remaining cases with ISS </=25 (n=1,003) were 
placed into the low patient acuity group (see Figure 1).  The sample was analyzed as a 
whole and the two patient acuity groups were studied independently in attempt to 
quantify the potential confounding of high patient acuity (see Table 2).  
Multiple binomial logistic regression (mBLR) was employed on the data set as a 
whole (N=1,055) to ascertain the effects of Any Antibiotics Taken (N,Y), Probiotics 
(N,Y), Sex (Female, Male), ICU days (N,Y), MV days (N,Y), ISS, ICU free days, LOS, 
and Age on the likelihood of developing an HAI. Linearity of the continuous variables 
with respect to the logit of the dependent variable was assessed via the Box-Tidwell 
(1962) procedure. A Bonferroni correction was applied using all fourteen terms in the 
model resulting in statistical significance being accepted when P < .00357 (Tabachnick & 
Fidell, 2014). Based on this assessment, all continuous independent variables were found 
to be linearly related to the logit of the dependent variable. Next, multicollinearity was 
assessed using a criteria of Variance Inflation Factor (VIF) >/= 3, which resulted in the 
removal of LOS (VIF=5.099) and ICU free days (VIF = 3.849). Following removal, 
reassessment of multicollinearity showed VIF of all remaining variables to be < 1.800. 
Twenty-four standardized residuals had an absolute value > 2 standard deviations; all 
were kept in the analysis. With a cut-value of 3.5%, the mBLR model was statistically 
significant, χ2(7) = 64.800, P < .0005 (Hosmer-Lemeshow Test, P = .617). The model 
explained 23% (Nagelkerke R2) of the variance in acquisition of an HAI, with a 78.9% 
overall percentage correct. Sensitivity was 77.8%, specificity was 78.9, positive 
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predictive value was 11.5% and negative predictive value was 99.0%. Of the seven 
predictor variables, two were statistically significant, as shown in Table 2.  
Two variables were revealed as statistically significant predictors of an HAI in this 
sample:   
 ICU days (categorized as 0 days and > 0 days),  
 Probiotics (No, Yes) 
 
 
  
B S.E. Wald df P 
Odds Ratio, 
[Exp(B)] 
95% C.I. for 
Odds Ratio 
  Lower Upper 
ICU days, cat(1) 1.866 0.472 15.626 1 0.000 6.461 2.562 16.293 
Probiotics (N,Y)(1) 1.261 0.384 10.764 1 0.001 3.528 1.661 7.492 
Any Antibiotics Taken(1) 0.788 0.427 3.402 1 0.065 2.199 0.952 5.082 
ISS 0.033 0.021 2.579 1 0.108 1.034 0.993 1.077 
Age 0.009 0.010 0.796 1 0.372 1.009 0.990 1.028 
Vent(1) 0.285 0.493 0.335 1 0.563 1.330 0.506 3.494 
Sex(1) -0.155 0.405 0.146 1 0.702 0.857 0.388 1.893 
Constant -6.022 0.975 38.139 1 0.000 0.002     
Table 2.  Results of the Multiple Binary Logistic Regression, N = 1,055 
 
The interpretation does not change when the above analysis is repeated following 
stratification by ISS. (See Table 3) 
ISS </= 25 
B S.E. Wald df Sig. 
Odds 
Ratio, 
Exp(B) 
95% C.I. for Odds 
Ratio 
Lower Upper 
ICU days, cat(1) 1.887 0.497 14.446 1 0.000 6.602 2.495 17.472 
Probioitcs 
(N,Y)(1) 1.442 0.442 10.668 1 0.001 4.230 1.780 10.050 
Any Antibiotics 
Taken(1) 0.845 0.488 3.004 1 0.083 2.328 0.895 6.054 
Age 0.011 0.011 0.969 1 0.325 1.011 0.989 1.034 
ISS 0.026 0.040 0.425 1 0.514 1.026 0.949 1.110 
Sex(1) 0.301 0.462 0.424 1 0.515 1.351 0.546 3.341 
Vent(1) -0.126 0.579 0.047 1 0.828 0.882 0.283 2.744 
Constant -6.388 1.156 30.505 1 0.000 0.002     
Table 3:  mBLR Output for Low Patient Acuity Group 
(Note:  Analysis of the ISS > 25 group is too underpowered for interpretation) 
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Figure 2:  AUC for mBLR, ISS 
</= 25, Outcome of Infection 
 
The area under the ROC curve 
was .817 (95% CI, .732 to 
.902), which is an excellent 
level of discrimination 
according to Hosmer et al. 
(2013).  
 
 
 
Obviously, the two unexpected results are:   
1) Taking an Antibiotic(s) is not a statistically significant variable and is associated with 
an increase in the odds of acquiring an HAI 
2) Taking Probiotics is a highly statistically significant variable and is associated with an 
increase in the odds of acquiring an HAI  
One reasonable and probable reason for this is demonstrated in Table 4.   
 
 Frequency 
Valid 
Percent 
Cumulative 
Percent 
 No Abx & No Probiotics 428 40.6 40.6 
Yes Abx & No Probiotics 466 44.2 84.7 
Yes Abx & Yes Probiotics 111 10.5 95.3 
No Abx & Yes Probiotics 50 4.7 100.0 
Total 1055 100.0  
Table 4:  Composite Variable: [Any Antibiotics Taken (N,Y) with Probiotics (N,Y)] 
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The probiotics protocol was not followed in 85% of the study sample. 
Furthermore, the mBLR suffers from a low event condition given an overall 3.4% 
infection rate (36/1,055).  
  Patient Acuity   
  Low 
(ISS </=25) 
High 
(ISS > 25) 
P-value 
N =  1003 52   
        
Infection rate, % 
(count) 
2.7 (27) 17 (9) < .0001 
        
LOS, days       
mean 5.66 9.9 
< .0005 
median 4 8 
mode 3 6 
   
Mortality, %       
lived 97 73 
< .0005 
died 3 27 
Sex, %       
female 60 46 
0.046 
male 40 54 
Age, years       
mean 70.91 60.54 
0.014 
median 76 62.50 
mode 86 78 
   
ISS       
mean 9.51 31.58 
< .0005 
median 9 29.50 
mode 9 26 
   
ICU free days       
mean 5.07 4.63 
0.142 
median 4 4 
mode 3 4 
   
ICU LOS, days       
mean 0.58 5.27 < .0005 
  
140 
 
median 0 3 
mode 0 0 
   
Table 2:  Comparison of patient acuity groups  
 
Probiotic usage 
 Clinician compliance with ordering probiotics remains a challenge to the 
investigation of the impact of probiotics on infection events. Prior to the probiotics 
protocol being incorporated into the (EPIC) electronic admission order set, only about 
10% of eligible patients received probiotics.  Although compliance increased afterwards, 
it remained suboptimal.  Overall compliance/usage rates for the study period were 15% 
(161/1,055), with a statistically significantly different compliance rate between the low 
patient acuity at 15% (147/1003) and high patient acuity group at 27% (14/52), (P < 
.0165, z-test for independent proportions.)  The data also revealed that, in addition to 
patients with an ISS > 25, those admitted to a general trauma surgical unit were also more 
likely to have received probiotics.  
Low Patient Acuity (ISS </=25)       
  Probiotics   
  Yes No P-value 
N =  147 856   
        
Infection rate, % (count) 8.2 (12) 1.8 (15) < .0001 
        
LOS, days       
mean 7.18 5.40 
< .0005 
median 5 4 
mode 3 3 
   
Mortality, %       
lived 97 97 
.807 
died 3 3 
Sex, %       
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female 63 60 
.399 
male 37 40 
Age, years       
mean 65.04 71.92 
.001 
median 70 77 
mode 86 86 
   
ISS       
mean 10.39 9.36 
.100 
median 9 9 
mode 9 9 
   
ICU free days       
mean 5.74 4.95 
.043 
median 4 4 
mode 3 3 
   
ICU LOS, days       
mean 1.40 0.44 
.026 
median 0 0 
mode 0 0 
   
Table 6:  Comparison between those that did and did not receive probiotics in the low patient acuity group 
Infection 
Of the 1,059 patients, 40 infections were recorded; 4 patients were excluded due to an 
infection event occurring prior to or on the same day as the start of probiotic usage.  
These 4 cases were excluded from final outcome analyses since probiotic administration 
could not have impacted the infection in these cases.  The infection event date could not 
be determined for the 23 infection events recorded in the trauma database, this being a 
major limitation that likely affects our analysis.  Of the remaining 36 infection events, 27 
infections occurred in the low patient acuity group (in 15 of those cases, the patient did 
not receive probiotics) and 9 infection events in the high patient acuity group (in 5 of 
those cases, the patient did not take probiotics).   
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 In the low patient acuity group, 8.2% of the patients who had probiotics also had 
had an infection (12/147), as compared with 1.8% infection rate for those who did not 
(15/186), In the high patient acuity group, 28.6% of patients taking probiotics had an 
infection (4/14), as compared to 13.2% infection rate for those who did not take 
probiotics (5/38). Although consistent with the mBLR analysis, these are unexpected 
results – that those patients taking probiotics had higher infection rates.  Note that 
although not statistically significant predictors of HAI by the mBLR, both ICU LOS and 
hospital LOS in the low acuity group, were statistically significantly longer for those that 
took probiotics versus those that did not.  
 
Mortality 
 Mortality rate in the patients not taking probiotics was 3.4% (29/856), as 
compared to 2.7% in those taking probiotics (4/147). Although there were differences 
between pre- and post- implementation of the addition of probiotics to the electronic 
order set, mortality was not statistically significantly different on probiotics, taken or not, 
(P = .807, Fisher’s Exact Test used due to an expected cell count < 5).   
MV days 
 A crosstab of MV days (N,Y) vs ISS category and MV days (N,Y) vs Probiotics 
(N,Y) for the low patient acuity group only showed a statistically significant association, 
Fisher’s Exact Test, P < .0005 and P = 018, respectively..  Importantly, the observed 
count of patients with > 0 vent days that took probiotics was 1.7x (17/9.8) more than 
expected, whereas all other (observed-expected) differences were within +/- 7.2 cases.  
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Hospital LOS 
 The positively skewed distributions of hospital LOS were not statistically 
significantly different between the probiotics and no probiotics groups, mean days = 5.44 
and 5.04, respectively.  Given homoscedasticity (Levene statistic = 2.123, P = .145) and 
violation of normality (Shapiro-Wilk, P < 0.0005), the Mann-Whitney U Test was 
applied (U = 59,025.500, z = 1.921, P < 0.055). 
 
Antibiotic requirements 
Consistent with the mBLR, a Chi-square crosstab of Any Abx taken and Pt Acuity 
Group is not statistically significant (P = .656).  However, a statistically significant 
association does exist between Any Antibiotic Taken and Probiotic Taken, (P < .0005), 
whereby a patient is about twice as likely to have both prescribed as opposed to either an 
antibiotic or probiotic alone. Furthermore, this finding is due to the low patient acuity 
group, P < .0005, versus P = .125 for high patient acuity (See Table 7). 
The statistical analysis strongly indicates the presence of treatment bias 
(probiotics and antibiotics), unmitigated confounding, and likely the need for additional 
explanatory variables, e.g. measurement of the GI microbiome (pre, during, and post 
treatment), timing of probiotics relative to other treatment (antibiotics), and duration of 
antibiotic and probiotic regiments. A 2:1, nearest neighbor without replacement 
propensity score matching (PSM) utilizing logistic regression estimation with a matching 
order of largest, caliper setting of .2, and probiotics as the treatment was employed in an 
attempt to combat the bias and confounding. The covariates included were: dichotomized 
ISS (split at 25), Any antibiotics (Yes/No), Any H2 blocker (Yes/No), Any PPI (Yes/No), 
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ICU days (Yes/No), Mechanical ventilation (Yes/No), LOS, ICU free days, Age, and 
Sex.  The PSM yielded a balanced (L1 from .859 to .707 and no unbalanced covariates) 
matched sample of: N = 446 with 16 infections (3.6%). The mBLR was rerun on this 
matched sample with no change in statistical interpretation from the original mBLR 
detailed previously.  
 
 
% (count) Low Patient Acuity 
Group 
High Patient Acuity 
Group 
N =  1003 52 
% treated with antibiotics 55% (547/1003)  58% (30/52) 
P - value .653 
Of those: 
% received probiotics 18% (100/547) 21% (11/52) 
P - value .610 
   
Statistical Test z-test for independent proportions 
Table 7:  Antibiotic Treatment Pattern by Patient Acuity 
 
 
 
Discussion 
 Two main issues prevent more definitive conclusions from the statistical analyses, 
namely, low infection rate (3.4%) and the compliance/usage rate of probiotics (15%).  
The utilization rate was likely negatively impacted by the conversion to EPIC and the 
process issues that followed during implementation.  However, it should be noted that 
similar ordering compliance rates were found with a study performed by Berry and 
colleagues(Berry, 2017).  They also found low utilization rates even after implementation 
of an electronic ordering system and formal recommendations of usage by the Medical 
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Executive Committee.  They concluded that practicing physicians were reluctant to order 
probiotics even after formal recommendation was made by the Medical Executive 
Committee and education took place.  The authors questioned whether ordering 
physicians had fear of active patient infection, lack of knowledge on probiotics, or 
whether other factors were influential in their decision.  This is an area for further study 
in our institution. 
Other than Injury Severity Score (ISS), an exhaustive investigation of patient 
acuity was not done due to difficulties with variables of interest not being available such 
as APACHE scores, co-morbidities; and surgical procedures performed - these are likely 
confounding variables.  Also, the low patient acuity group was shown to have statistically 
significantly values of LOS and MV occurrence that would likely place those patients at a 
higher risk of infection.  
 
Limitations 
 Our study had several limitations.  First, as outlined above, it was conducted 
during a period of paper to electronic ordering modification which likely contributed to 
lower than expected probiotic utilization rates.  Next, low infection rates relative to 
sample size, particularly after ISS stratification, produced a study that was nontrivially 
statistically underpowered. There also was a disparity in sample size between the 12 
months prior to inclusion of the probiotics order set in electronic admission orders (n= 
680) and the 6 months afterwards (n=379).   The timing of the initiation of probiotics in 
relation to the onset of infection was impossible to determine in the trauma database.  
Although we did exclude 4 infection events based on the timing of initiation of probiotic 
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usage, there likely were more events that should have been excluded.  Further, it is not 
known how long or how many doses of a probiotic one must take to replenish lost 
microbiota, so further investigation into this related to infection onset date should be 
more closely examined.  Besides ISS scores, other potential confounding variables that 
may influence infection were not specifically tracked; namely other means of 
determining acuity (APACHE, etc.), co-morbid conditions, previous infections, or 
surgeries.  We had no knowledge of the patients’ GI microbiome prior to injury. Lastly, 
this was conducted at a single medical center. 
 
Future Studies 
 First, investigation into reasoning for the low probiotic utilization rates should be 
performed and a plan should be developed to increase compliance with the probiotics 
protocol as indicated.  Another area for investigation is to examine individual provider 
compliance with the protocol.  Ordering compliance between attending physician, 
resident, or trauma nurse practitioners may be different.  Once increased utilization is 
realized, strength of statistical analyses should improve to perhaps provide more solid 
answers to the research questions.  Also, potential co-morbid factors as discussed earlier 
should be considered when examining the impact probiotics may or may not have on 
infection risk.  This may be influential if a larger sample size is available.  
 
Conclusions 
 The analyses reveal the importance of hospital processes, specifically regarding 
the ordering (yes/no) and timing of the probiotics protocol.  Probiotics usage seemed to 
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trend higher for sicker patients and were ordered with increased frequency on certain 
hospital units.  Further, being a relatively novel adjunct therapy that clinicians may not 
know about or fully trust, communication about the ordering of probiotics needs to be 
intense and frequent.  In this hospital, residents rotate through the trauma service so 
communication regarding the expectation for ordering probiotics should be clear.  This 
study reached no definitive conclusions regarding the use of probiotics in trauma patients.  
Some possible reasons for this lack of conclusions may by explained for reasons already 
stated. However, given the inconclusiveness of past research that has shown both benefit 
as well as the drawbacks of probiotic use speaks to the necessity of further research.  
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Summary of Key Points 
 
Healthcare-associated infections are a costly complication of hospitalization.  Hospitals 
are implementing prevention strategies with modest success.  New and novel approaches 
for the prevention of HAIs must be explored. 
 
 Although literature shows that benefits of probiotics likely outweigh any potential risks, 
some providers may still be hesitant to order them for acutely ill patients 
 
 Trauma patients are at increased risk for the development of an HAI due to the nature of 
a traumatic injury, but as a result of a host of other factors as well 
 
 Additional research is warranted in pursuit of ascertaining the appropriate use case(s), 
utility and interaction effects of probiotic usage in the trauma population 
 
 No adverse events related to the administration of probiotics were identified in this study 
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